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Abstract 
 
Macrophages are cells from the innate branch of immune system with central roles both 
under physiologic and pathologic conditions. Such complex behaviour relies on extreme 
functional plasticity of these cells. Cellular activation and plasticity in macrophages are 
complex phenomena that require tight regulation. In recent years, microRNAs and 
lncRNAs emerged as important regulators of many cellular processes and have been 
proposed as key mediators of the plasticity observed in macrophages.  
In this study we investigate the possible roles of different microRNAs on macrophage 
activation and functionality, taking advantage of animal models selectively depleted of 
candidate miRNA in macrophages.  
We found that selective depletion of miR-125a in macrophages did not affect clinical 
outcome in different in vivo models of inflammation. Nonetheless it altered macrophage 
activation and functions, as evidenced by reduced secretion of TNFα after endotoxin 
challenges. Consistently, macrophages deficient in miR-125a displayed reduced killing 
of extracellular bacteria although they showed increased phagocytic rate as compared to 
miR-125a competent cells.  
With a similar approach, we confirmed that miR-9 is induced in macrophages upon 
inflammatory stimuli. Increased expression of miR-9 mature form in mice was sustained 
by the synchronous activation of transcription in both pri-miR-9.1 and pri-miR-9.3 loci, 
in contrast to human. 
Finally we identified a lncRNA interfering with the processing of a pro-inflammatory 
miRNA in differentially activated human macrophages, highlighting a new layer of 
regulation of macrophage activation.  
The finding of the present project give new insights into the complex mechanism 
regulating macrophage activation and underscores the need for future studies to 
thoroughly identify the molecular mechanisms and the involvement of different miRNA 
in macrophage activation. Moreover, such studies could set the basis for the transition 
from basic research to new therapeutic options enabling precise regulation of 
macrophages activation in different immune pathologies.
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Introduction 
 
1 The Mononuclear Phagocytic System 
 
1.1 Monocytes 
 
Monocytes are cells from the innate immune system. They originate from precursors in 
the bone marrow, whose development is guided by the sequential effect of different 
factors like granulocyte/macrophage-colony stimulation factor (GM-CSF) and 
macrophage-colony stimulation factor (M-CSF). At the end of their differentiation, 
monocytes are characterised by dimensions slightly bigger than lymphocytes, with a 
round shape and a roughly circular or kidney-shaped nucleus. Mature monocytes 
mobilise from bone marrow to the blood stream where their lifespan is between one and 
three days for human. From there, monocytes can leave circulation and infiltrate tissues 
where they differentiate into macrophages. Such fate, from BM to blood and finally to 
tissues differentiating into macrophages, was once held as a paradigm for monocytes 
but now it is increasingly clear that several exceptions exist. For example, it has been 
shown that mature monocytes can leave the blood stream and settle in the spleen, where 
they may constitute a functional reservoir 2, or they can even return to the bone marrow 
with yet unclear functions 3. On the one hand monocytes can leave circulation as a result 
of inflammatory stimuli, infiltrating affected tissues and head toward the source of 
inflammation where they finally differentiate into macrophages, in order to orchestrate 
subsequent phases of inflammatory response. On the other hand however, it is now clear 
that at steady state monocytes are responsible for replenishment of tissue resident 
macrophages only in a fraction of tissues 4. For many other tissues, as for instance the 
brain, macrophages originate from cells migrating from the Yolk sack during fetal 
development and are maintained by local proliferation rather than recruitment of 
mononcytes from the blood 5. Once considered a homogeneous population, circulating 
monocytes have been shown to be sub-divided in three distinct subsets based on 
differences in the expression levels of two surface markers. In humans, monocytes have 
been divided between ‘classical, inflammatory’ monocytes expressing high levels of 
CD14 (a coreceptor of TLR4 for LPS) but low levels of CD16 (a subunit of receptors 
for antibody’s invariant chains) and ‘alternative’ monocytes with low CD14 but high 
CD16 expression. A third group, however, has been identified with intermediate 
expression levels for both markers 6. Since spontaneous conversion between two major 
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subtypes has been proposed for human monocytes, the ‘intermediate’ class may 
represent a transition class resulting from ongoing conversion process. In murine 
context similar subdivisions have been outlined using two different markers: Ly6C 
high/CD43 low monocytes that roughly correspond to inflammatory monocytes in 
human; Ly6C low/CD43 that highly resemble alternative monocytes 7. Differently from 
human monocytes, spontaneous conversion between cellular subtypes has been proven 
in mice 8. Furthermore, besides being the precursors of macrophages in tissues, 
monocytes also play a role in the bloodstream. Circulating monocytes already display 
many of the functions of the mature macrophages like phagocytosis, antigen 
presentation through MHC-II, cytokines production and migration along a chemotactic 
gradient. Thus monocytes are also involved in immune-surveillance, patrolling the 
blood stream. As such, they are involved in many pathological processes. The 
proportion of these cells in the circulation as well as the relative frequencies of different 
subsets may change under different pathological conditions.  
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1.2 Macrophages 
 
1.2.1 Macrophage Biology 
 
Macrophages are cells of big dimensions that dwell in tissues or differentiate there from 
circulating monocytes during inflammatory response. Once considered a single cell 
type, they are now recognised as highly plastic and heterogeneous cells. This feature 
was the reason for the development of the new ‘Mononuclear Phagocytic System’ 
concept 9. The first layer of plasticity in macrophages is ontogenic. During fetal 
development a first wave of macrophages differentiates from yolk sack (YS) and 
migrates to colonise different tissues like brain, liver, lung, pancreas, skin and spleen 10. 
Here, thanks to molecular signals produced locally, macrophages terminally 
differentiate and develop characteristics exclusive of the hosting tissue. A second wave 
of macrophages develops at later stages, originating from fetal liver and colonising skin 
and mucosa, giving birth to Langerhans Cells 11. Finally, after birth, hematopoiesis takes 
place in the bone marrow. Here common myeloid precursors differentiate to monocytes 
that patrol the blood stream, eventually leaving circulation to infiltrate tissues and 
differentiate into macrophages. To add complexity to the scheme, depending on the 
tissue, local proliferation rather than recruitment of circulating precursors may be 
responsible of macrophage replenishment in tissues both physiologically or following 
infection 5. Furthermore, in the same tissue may reside macrophages of different origin, 
exerting different functions 12. Macrophage plasticity is particularly evident under 
pathological conditions. During inflammatory response many of the molecules produced 
have specific effects on macrophage phenotype. Bacterial moieties and type 1 
inflammatory cytokines like IFNγ direct macrophages to a ‘classically activated’ state 
(M1), primed to sustain inflammation by producing pro-inflammatory cytokines like 
TNFα, IL12 and chemokines like CXCL10. On the contrary, type 2 cytokines like IL4 
and IL13, together with anti-inflammatory cytokines like IL10 and TGFβ, induce an 
‘alternatively activated’ state in macrophages (M2) that result in increased secretion of 
anti-inflammatory molecules and enhanced tissue remodelling and repair 13. The 
M1/M2 dichotomy was originally based on in vitro studies but is unlikely to resemble in 
vivo complexity. In fact, a wide panel of stimuli has been proved to induce macrophage 
activation states intermediate between M1 and M2 14. Hence, these extreme polarised 
phenotypes are rather considered a paradigmatic reference, delimiting the spectrum of 
possible active macrophage state. Moreover, further blurring the boundaries between 
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activation states and proving once more the uncommon plasticity of these cells, 
macrophage polarisation is not a fixed state but rather changes accordingly with changes 
in the surrounding microenvironment 15. Lastly, macrophage plasticity is strictly related 
to timing. In vitro, macrophages exposed to unique specific stimuli sequentially activate 
distinct sets of genes 16. This dynamic process depends on different mechanisms such as 
epigenetic and biochemical changes or autocrine effect of secreted cytokines. Another 
important feature tightly linked to plasticity is the idea that these cells may display 
varying degrees of memory 17. Cellular memory is the ability to adapt cellular responses 
according to previous experiences. In the case of macrophages it has been shown that 
repetitive stimulation with bacterial moieties like LPS decrease macrophage response, a 
condition termed endotoxin tolerance 18. Moreover, a recent report claimed that during 
infections in Drosophila, macrophage ability to engulf microbes requires that the same 
cells previously participated in physiological phagocytosis of apoptotic cells during 
embryonic development 19. The extent and duration of trained macrophage responses is 
still matter of debate, as well as the molecular mechanisms at the basis of innate 
memory. Metabolic changes have been observed in macrophages following pathogen 
recognition and were proposed to sustain memory in such cells 20, but are unlikely to 
last long. A more effective mechanism that may store memories over a longer period of 
time might rely on epigenetic changes.  
As a reflection of their great ductility, macrophages display several cellular functions, 
thus playing multiple roles both under physiological and pathological conditions. The 
main feature of these cells, that also gained them their name, is phagocytosis. 
Macrophages are not the only cells in the organism with phagocytic ability, but they are 
by far the most specialised cells for this process, given the wide array of functional 
phagocitic receptors displayed 21. Phagocytosis is a process by which particles external 
to the cell can be internalised by means of lipid bilayered vesicle originating from the 
cell membrane called ‘phagosome’. The aims of this process include removal of cellular 
debris or noxious agents and collection of information on the extracellulare milieu to be 
shared with other cells, above all lymphocytes. Phagocytosis occurs through different 
mechanisms always requiring molecular interactions between the particle to be engulfed 
with a surface receptor, remodelling of the actin cytoskeleton and the formation of an 
immature phagosome 22. Immature phagosome maturates through several rounds of 
fusion with other intracellular vesicles like lysosoma and other endosomes, 
progressively dismantling phagocytised particles 23. Phagocytosis may occur through a 
‘zippering’ mechanism, in which interaction between phagocytic receptors, like FcR 
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and Dectin, and their ligands leads to receptor clusterization that force the surface 
membrane to protrude, finally embracing the target particle 24. Other receptors, like 
complement receptors, upon interaction with opsonized target induce the rearrangement 
of actin cytoskeleton pulling in the particles, a process termed ‘Sinking’ phagocytosis 25. 
A third mechanism that result in vesicle formation from the plasma membrane with 
internalisation of materials from the extracellular matrix is ‘triggered’ phagocytosis or 
‘macropinocytosis’ 26. Macropinocytosis is a common method shared by several cell 
types across the organism to sense the extracellular space. It occurs in a non-specific 
way following receptor triggering, making it difficult to strictly define what a 
phagocytic receptor is. In macrophages, macropinocytosis can be triggered by a wide 
array of receptors, including TLRs. Therefore, it has been proposed as a method by 
which, under inflammatory conditions, macrophages could increase the harvest of 
extracellular antigens to further process and expose for lymphocyte activation 27. 
Phagocytic particle usually are recognised by more than one receptor. Functional 
redundancy in receptors and mechanisms make it difficult for a pathogen to completely 
avoid phagocytosis and guarantee a better profiling of the threat by macrophages. 
Indeed, along with internalisation, phagocytic receptors also trigger several signaling 
cascades, tailoring the response onto the challenged pathogen. The fate of internalised 
vesicles depends on a great amount of variables, including nature and dimensions of the 
particle and the array of receptors involved. During vesicle maturation, the degradation 
of the phagosome content by fusion with acidic lysosome may lead to the exposure of 
new binding sites, thus triggering new responses or enhancing previously activated 
signaling pathway 28. Finally, the content of the matured phagosome may be exposed on 
cell surface, usually by means of mayor histocompatibility complex class II (MHC-II) 
molecules, but cross-presentation via MHC-I also has been described when 
pahgocytosis occurs through DNGR-1 triggering 29. In some cases, like in the case of 
phagocytosis of apoptotic bodies, internalisation of target is immunologically silent, not 
arising any inflammatory response 30. 
During infection of noxious pathogens, the internalisation alone, although limiting 
nutrient supply for bacteria, is insufficient to kill microbe. Indeed maturation of 
phagosomes containing bacteria recruits several other antimicrobial effectors. 
Acidification of the phagolysosome serves both the purpose of bacteriostasis and 
enhancement of degradative ability of lysosomal enzymes 31. In addition, macrophages 
mount an effective antimicrobic response recruiting NADPH oxidase (NOX2) to the 
phagosome surface. NOX2 is composed of two multimeric complexes, one of which is 
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integral to the cell membrane (and therefore to the phagosomal membrane upon 
formation), while the other is cytosolic and is recruited to the surface following 
activation signals 32. NOX2 oxidises cytoplasmic NADPH to NADP+ and transfers 
electons to molecular oxygen in phagosomal lumen to produce O-. Radical oxygen can 
further react to generate H2O2, subsequently dismuted to OH- by Fenton reaction. 
These molecules, commonly referred to as Reactive Oxygen Species (ROS), are highly 
toxic to living being due to their radical nature that triggers chain oxidative reactions in 
biological macromolecules. Along with ROS production, inflammatory stimuli also 
induce expression of the inducible nitric oxide synthase (iNOS) enzyme that oxidise 
NADPH and arginine to produce cytosolic NO and citrulline. NO can diffuse to the 
lumen of the phagosome and further react with ROS to generate the highly toxic 
peroxynitrite (ONOO-). Macrophages also exert microbicidal activities on extracellular 
pathogens by secreting lytic enzymes like lysozymes and members of the cathelicidins 
class 33. Oxidation and degradation of phagocytised particles allow efficient loading of 
antigens onto MHC-II and extracellular presentation 34. MHC-II consists of two 
subunits (α and β chains) that assemble in the Endoplasmic Reticulum (ER). Initially 
MHC-II peptide-binding groove is masked by an Invariant chain (Ii) that also stabilize 
the interaction of α and β chains. Immature MHC-II:Ii complexes are transported 
through the Golgi apparatus via transport vesicle to finally reach a specific compartment 
(termed MHC class II Compartment, MIIC). Here Ii is partially degraded by acidic pH 
and cathepsins, leaving a residual ClassII-associated Ii Peptide (CLIP) to cover the 
antigen-binding groove at the α:β interaction face. Vesicles from MIIC carrying 
matured MHC-II:CLIP complexes subsequently fuse with vesicles from the 
endophagocytic system, CLIP is exchanged for the antigenic peptide (of extracellular 
origin) thanks to the chaperone protein HLA-DM. Finally, the vesicle carrying the fully 
mature MHC-II:antigen complex fuse with plasma membrane exposing the processed 
antigen on cell surface. Extracellular antigen presentation is peculiar to specialised 
phagocytes, like macrophages, monocytes, DC and B-lymphocytes. Antigen 
presentation through MHC-II directs adaptive immune response toward specific 
pathogens, but alone is generally insufficient to induce T-cell activation. In order to 
trigger an efficient activation of T lymphocytes against common antigens, costimulatory 
molecules must be expressed on antigen presenting cell (APC) surface 35. Activation of 
lymphocytes is further boosted by macrophages through secretion of soluble mediators 
of inflammations like cytokines and chemokines (extensively reviewed in Arango 
Duque and Descoteaux 2014 36). In brief, classically activated macrophages secrete a 
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plethora of pro-inflammatory cytokines that have pleiotropic effects such as TNFα, IL6, 
IL1, IL12, IL18, IL23 and IL27. The release of these molecules is accompanied by 
secretion of pro-inflammatory chemokines that recruit other cell types to the inflamed 
site. CXCL1/2, CCL2, CXCL8/9/10/11 are the inflammatory chemokines produced by 
M1 macrophages that sustain inflammation. On the contrary, alternatively activated 
macrophages and macrophages involved in resolution of inflammation switch the set of 
molecules secreted, preferentially releasing the anti-inflammatory molecules IL10 and 
TGFβ, together with CCL1, CCL17, CCL22 and CCL24 chemokines. Thanks to this 
wide array of soluble mediators produced, macrophages are master regulators of the 
inflammatory process in all of its phases. Macrophages also play an important role in 
angiogenesis. In fact they secrete important mediators that prime endothelial cells for 
new vessel formation, like WNT7 37 and VEGF 38; moreover macrophages can establish 
direct cell-to-cell contact with sprouting endothelial cells 39 and secrete matrix 
remodelling enzymes 40. Macrophage control of angiogenesis is of key importance 
during ontogenesis 41, wound healing 42 and for cancer progression and metastasis 43. 
 
1.2.2 Macrophage Role in Pathology 
 
1.2.2.1 Resolution of inflammation 
Inflammation is a necessary response developed by the organism to maintain integrity 
and fight infections. But, since persistent inflammation may be deleterious, it must be 
temporally limited. Initially, resolution of inflammation was considered a passive 
process consequent to the eradication of noxious stimuli that triggered the immune 
response. It is now widely accepted that resolution of inflammation is instead an active 
and complex phenomena that requires synergistic action of molecules produced by 
different immune cell types. Although resolution of inflammation is a choral effort, 
master regulators of the process appear to be macrophages. In fact macrophage 
depletion results in a prolonged influx of neutrophils in infected tissue (Chadzinska et al 
2004) and increased systemic dissemination of pathogens 44. Pro-resolving macrophages 
inhibits neutrophil recruitment through secretion of matrix metalloprotease 12 
(MMP12). This enzyme cleaves the CXC chemokines in the ELR arm, thus impairing 
receptor binding, and CC chemokines like CCL7. Cleaved CCL7 is still able to bind its 
receptors but fails to induce signal transduction, thus acting as a pharmacological 
antagonist 45. Pro-resolving macrophages not only inhibit neutrophil recruitment, but 
also remove dying neutrophils in a process termed ‘Efferocytosis’ 46. Efferocytosis is a 
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tightly regulated process that require neutrophil release of soluble find me signals like 
lysophosphatidylcholine 47, sphingosine-1-phosphate 48, CXCL3 49 and nucleotides 50. 
Find me signals attract macrophages and the exposure of eat me signals like annexin-A1 
51 and phosphatidylserine (PS) 52 on dying neutrophil cell surface trigger phagocytosis. 
Entrance in the resolving phase of inflammation is madiated by a marked switch in 
macrophage activity. Intrinsic autoregulatory loops triggered by PRR activation in these 
cells result in the expression of the anti-inflammatory IL10 cytokine 53. Autocrine 
exposure to IL10 in macrophages leads to switch off of pro-inflammatory signaling 
pathways and expression of genes important for resolution of inflammation 54. In 
particular, IL10 in macrophages reduce the expression of COX2 and favour the 
expression of COX1 together with Arachidonate-15-lipoxigenase. These molecules 
cooperate to convert arachidonic acid into lipid mediators of resolution called lipoxins 
and resolvins 55. Resolution of inflammation has been extensively studied in animal 
models. Intraperitoneal (IP) injection of a yeast lysate (Zymosan) results in an acute 
peritonitis that spontaneously resolves in 48 to 72 hours 56. In such model, cellular 
dynamics have been analysed highlighting a transient increase of neutrophils in the 
peritoneal cavity that peaked between 4 and 12 hours post stimulation. Neutrophil influx 
decrease over time and monocytes take the stage. Forty eight hours after stimulation, 
more than 60% of leukocytes in peritoneal lavage are reported to be macrophages. Since 
miRNA are known to regulate complex cellular processes, it is possible that they are at 
least in part responsible for macrophage phenotypic switch that regulate the entrance in 
resolving phases of inflammation and recent data indicate that that is indeed the case 57.  
 
1.2.2.2 Colitis 
Gastrointestinal tract (GI) is a site of direct contact between the self organism and the 
non-self environment. Differently from other interfaces between self/non-self like the 
skin, in GI tract an extensive exchange of molecules and nutrients must take place to 
grant survival of the organism. In vertebrates, GI tract is colonised by a myriad of 
microbs that are collectively referred to as ‘microbiota’ 58. Microbiota exerts many 
functions that are key for the digestive process. Massive presence of microbs in the 
intestinal lumen poses a serious task to the host immune system. In fact, although 
beneficial bacteria from the microbiota are indistinguishable from pathogenic ones by 
innate immune cells, they must be tolerated for the sake of the organism. This goal is 
achieved by different mechanisms that maintain an anti-inflammatory environment and 
tolerance toward commensal bacteria 59. Intestinal macrophages are key contributors for 
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the maintaining of anti-inflammatory homeostatic environment. Although GI tract, like 
other tissues, is initially colonised by macrophages during fetal development, these cells 
are gradually substituted by macrophages differentiated from circulating monocytes 60. 
Monocytes in the intestinal microenvironment differentiate toward CX3CR1 
macrophages that exhibit anti-inflammatory properties 61. Anti-Inflammatory 
microenvironment in the GI tract is mainly maintained by IL10. In fact, genetic ablation 
of IL10 resulted in spontaneous inflammation in mice that was neutralised by IL10 
administration 62. Upon inflammatory imbalance in the gut microenvironment, increased 
permeability of the mucosa and infection by pathogenic bacteria species the tolerance is 
broken and inflammatory bowel diseases (IBD) like colitis occur. During colitis 
increased inflammatory cell infiltration in the lamina propria leads to severe alteration 
of the luminal surface of the colon with reduced mucin secretion, epithelial hyperplasia, 
abscess formation in the kripts. These alterations result in tissue ulceration with internal 
blood loss. Back in the 90s an experimental model of colitis was settled 63. It consisted 
in exposing mice to freely accessible water-dissolved dextran sulfate sodium (DSS) for 
almost a week, followed by a recovery period in which pure water was reintroduced. 
DSS leads to mucosal irritation and colitis with clinical features that recall human 
ulcerative colitis. Taking advantage of this setting, anti-inflammatory effect of IL10 has 
been restricted to its role in macrophages. In fact genetic KO of the IL10 receptor α-
chain resulted in worsening of the DSS induced colitis only when deletion was 
restricted to macrophages while it had no effect when deletion occurred in DC, B cells 
or T cells 64. Furthermore, concomitant neutrophil depletion using an α-Ly6G antibody 
had no effect in clinical outcome, further restricting IL10 effect to macrophages. 
Interestingly, differences in disease severity were not accompanied by differences in 
macrophage number nor in surface expression levels of activatory markers. Therefore it 
appears that macrophages play pivotal role in intestinal homeostasis and pathology. 
 
1.2.2.3 Sepsis 
Sepsis is defined as a systemic inflammatory response to infection. Of note, septicaemia 
is not always a feature of sepsis, suggesting that soluble elements originating from the 
primary infection site may be sufficient to trigger sepsis. The term ‘severe sepsis’ is 
employed when systemic inflammation results in organ dysfunction or insufficiency. 
‘Septic shock’ instead refers to conditions of systemic inflammation with refractory 
hypotension. Adding complexity, sepsis may occur as a systemic inflammatory response 
syndrome (SIRS) or a compensatory anti-inflammatory response syndrome (CARS) or 
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both syndromes may take place sequentially 65. SIRS is characterised by high levels of 
pro-inflammatory cytokines in plasma of patients and haemostatic abnormalities that 
may result in disseminated intravasal coagulation (DIC). High TNFα levels and DIC are 
main actors of multi-organ failure that occurs in severe sepsis and may cause patient 
death within few days. Nonetheless, treatment with anti TNFα antibodies failed to 
increase survival in clinical studies on patients with SIRS 66. On the contrary, CARS is 
characterised by an anergic state of immune cells that fail to respond to common 
stimuli. It often occurs after sepsis with septicaemia or extensive trauma and burn. Also 
CARS reactions are life threatening since pathogen superinfections may occur and 
result in retarded death. Features similar to SIRS, like hemodinamic shock, transient 
increase in TNFα accompanied by sustained increase in IL6 in plasma and rapid death 
have been observed in experimental animals injected intravenously (IV) or IP with LPS 
67. While repetitive stimulation with sub-lethal doses of LPS trained mice to survive to 
otherwise lethal doses of endotoxin 68. This effect is called endotoxin tolerance (ET) and 
may be considered an experimental model mimicking CARS features. Since monocytes 
are the major source of TNFα in the blood and are the only circulating cell population 
that do not undergo massive apoptosis during CARS, they appear to be the best 
candidates as regulators of both edges of pathology in sepsis. Interestingly, since the 
deactivation observed in CARS may be considered a form of cellular memory, 
epigenetic mechanisms are likely to intervene. Indeed possible miRNA contributions to 
pathogenesis of CARS have been proposed 69. 
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2 The non-coding Genome 
 
Back in 1950s a great series of discoveries in molecular biology were condensed by 
Francis Crick in the idea that genetic information is stored in DNA and converted to 
protein effector molecules by mean of an RNA intermediary 70. According to this idea, 
major focus converged on identifying and annotating protein-coding genes, while the 
noncoding regions of DNA were considered as ‘junk DNA’, inert genetic material 
accumulated with evolution. Although ribosomal RNA and transfer-RNA were already 
known, they were considered exceptions necessary for information flow from DNA to 
proteins. The central dogma has been initially shaken by the discovery of RNA 
molecules with enzymatic activity in 1980s 71. Further evidences of functional activity 
of RNA molecules came in the 1990s with the discovery of RNA interference, initially 
proven in insects and plants but later confirmed also in mammals 72. RNA interference 
refers to the ability of short stretches of RNA (siRNA or miRNA) to assemble into 
riboproteic complexes and bind by complementarity to mRNA molecules, inhibiting 
their translation to protein, eventually leading to their degradation 73. The advent of 
Next Generation Sequencing 74 techniques finally proved that only half of the 
transcriptome is protein coding, while the remaining part is composed of RNA 
molecules with no translational potential 75. Many of these noncoding RNAs are 
currently under investigation and for many of them structural or regulatory roles have 
been identified. 
 
2.1 MicroRNA 
 
MicroRNA in their mature form are RNA molecules as short as 20-22 nucleotides that 
exert negative regulatory effects on mRNA translation. In the genome, microRNA can 
be found alone or more commonly in clusters and are localized in intergenic region or 
intronic regions. As a consequence, these miRNA genes can rely on independent 
promoters or be dependent on the host gene expression, although little is known about 
the regulation of miRNA expression. MicroRNA originate from longer precursors 
transcribed in the nucleus into primary transcript microRNA (pri-miRNA). Since pri-
miRNAs often display 5’-capping and 3‘polyadenilation, they are considered to be 
mainly transcribed by Pol II, although in some cases Pol III is responsible for pri-
miRNA transcription. Pri-miRNA are characterised by hairpin structures that undergo 
further processing finally resulting in mature miRNA. Hairpins are recognised by a type 
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II endonuclease complex composed of DGCR8 and Drosha subunits that binds to a 
characteristic mismatch at the basis of the stem and excide it, leaving two overhanging 
nucleotides at 3’ end. Excided stem-loops are precursors of microRNA (pre-miRNA) 
and are exported to the cytoplasm by exportin V that recognise the overhanging 
nucleotides left by Drosha. In the cytoplasm pre-miRNA are further cleaved by another 
endonuclease, the Dicer enzyme, that cuts the loop between 5p and 3p arms, leaving an 
imperfect miR-5p:miR-3p duplex. The duplex denatures and one of the arms is loaded 
in the RISC complex. Selection of the arm to be loaded probably relies on intrinsic 
thermodynamical stability and binding strength between the 5’ end of miRNA strand 
and the protein complex. The main core of RISC complex are proteins from the 
Argonaute 76 or the PIWI families. These proteins are characterised by PIWI and PAZ 
RNA binding motives that interact with both overhanging nucleotides produced in 
miRNA strand by nuclease activity and target mRNA. Moreover, thanks to their 
structural similarity with RNAse-H enzymatic site, these domains may display 
ribonuclease activity. Although for most miRNAs only one of the arms is generally 
recruited in the RISC complex while the other undergoes degradation, for some 
miRNAs both strands may be loaded. The selected miRNA strand directs the riboproteic 
complex to its molecular targets and mediates translational silencing through different 
mechanisms. Perfect complementarity between miRNA and target mRNA results in 
target degradation (in human only Ago2 displayed nuclease ability) while incomplete 
binding leads to mRNA silencing either by competition with ribosome binding or by 
sequestering the ribonucleic complex to Processing Bodies (P-bodies) 77. The 
interaction between miRNA and target mRNA is complex. The critical region for 
miRNA:target interaction is termed seed. It consists of a region of perfect match 
generally spanning 6 or 7 nucleotides (respectively referred to as 6mer or 7mer seed) 
from position 2 at the 5’ end of RISC-loaded mature miRNA 78. Additional regions of 
complementarity external to the seed may further stabilise the interaction but are not 
critical for target recognition 79. Since complementarity is restricted to the short 
sequence of the seed region every miRNA is allowed to bind a wide array of different 
targets. This feature candidated miRNAs as regulatory molecules able to finely tune 
complex cellular processes. Indeed a wide corpus of literature has been collected linking 
microRNA activity to extensive multistep control of inflammation 80. Recent data show 
that miRNA play pivotal role already during cellular specification in the bone marrow 
81,82. In Acute Myeloid Leukaemia (AML) treatment of immature blasts with PMA 
resulted in partial unlocking of differentiation toward monocytic fate through 
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overexpression of a panel of miRNAs (namely, miR-155, miR-222, miR-424 and miR-
503; Forrest et al 2010). Interestingly, among the molecules identified as targets for 
these miRNAs mediating such an effect, a precursor for another miR stood out. Hence, 
microRNAs can both act maintaining an immature state or promoting cellular 
differentiation. MiRNAs also play a role during macrophage differentiation. Indeed 
microRNAs have been identified interfering at multiple levels with the machinery for 
M-CSF or GM-CSF signal transduction 83,84. More in general miRNAs may well be 
responsible at least in part of different features of macrophage plasticity. In fact many of 
these molecules have been linked to polarized states of activation in macrophages. 
Several microRNAs establish complex crosstalks with transcription factors relevant for 
polarised macrophage response 85,86. As an example, one of the prototypical M1 
miRNA, miR-155, is induced in macrophages by NFkB p50:p65 activation and exerts a 
pro-inflammatory effect by directly targeting transcription factors like C/EBPb that are 
important for anti-inflammatory phenotypes 87. 
 
2.1.1 miR-9 
 
MicroRNA-9 was initially identified as one of the most highly expressed miRNA in 
neural development 76,88. Mir-9 gene exists in three different isoforms, each mapping in 
a different chromosome. In non-neural tissues and in adult brain, miR-9 expression is 
inhibited by extensive methylation of CpG islands in miR-9 gene promoters. 
Interestingly, a lncRNA was recently reported to mediate methylation in miR-9 
promoters 89, while miR-9 was shown to negatively regulate the lncRNA MALAT1 90, 
further extending the known interconnections between ncRNA classes. In neural 
precursor cells miR-9 expression favours proliferation by inhibiting migration 91. 
Therefore it is not surprising that miR-9 alterations contribute to many malignant 
features of different tumour types. Interestingly, high levels of miR-9 increased motility 
of epithelial cells in human breast cancer 92 and many types of solid tumours are able to 
secrete miR-9 in microvescicles, inducing motility and migration in vascular endothelial 
cells, that result in increased angiogenesis 93. These results suggest that miR-9 effect on 
motility and migration is dependent on cell type. In fact, in other tumour types miR-9 
antagonises cell migration 94. Since miR-9 in non-neural tissues is not expressed at 
steady state, miR-9 expression in tumour cells is a late acquired feature that may confer 
pro-metastatic abilities. In the immune system, miR-9, more specifically miR-9.1 gene 
was shown to be induced both in monocytes and neutrophils upon stimulation with pro-
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inflammatory molecules in human 95. In the same report, NFkB was identified as a 
target of miR-9, suggesting that this miRNA may form a negative feedback that contrast 
cellular pro-inflammatory activation. More recently, ectopic expression of miR-9 in 
immature myeloid precursors led to altered neutrophil development 96. Indeed 
overexpression of this microRNA has been observed in cases of acute myeloid 
leukaemia (AML). Therefore it appears that miR-9 might play multiple roles in innate 
immune cells, regulating differentiation process, activation and maybe migration. 
Further studies are needed to fully understand miR-9 role in such contexts. 
 
2.1.2 miR-125a 
 
MiR-125 family comprises three miRNA isoforms that share the same seed sequence. It 
includes miR-125a located in chromosome 19q13, miR-125b-1 in chr.11q23 and miR-
125b-2 mapping in chr.21q21. The role of this miRNA family is still elusive. In fact, 
they have been reported to exert opposite functions in different tumour types 97  98. Also 
in autoimmune diseases these miRNA appear to have different effects in different 
pathologies. As an example, miR-125a levels are reduced in patients with systemic 
lupus erythemathosus (SLE) 99 but increased in rheumatoid arthritis 100. In SLE reduced 
levels of miR-125a result in increased expression of its target KLF13 that is a 
transcription factor for the inflammatory cytokine RANTES. In the immune system 
miR-125a plays multiple important roles. It is mostly expressed in long-term 
hematopoietic stem cells (HSC) and is progressively lost during differentiation 1. In 
HSCs apparently miR-125a is important for the maintenance of staminality although 
conflicting reports suggest that miR-125a overexpression in HSC leads to BM 
exhaustion 101. Moreover, miR-125a may also play a role in haematopoiesis regulating 
myeloid differentiation. In fact miR-125a overexpression blocks erythroid 
differentiation and results in myelodisplastic syndrome like acute myeloid leukaemia 
(AML) 102. In addition, a recent paper showed that genetic ablation of this miRNA leads 
to decreased number of circulating neutrophils 103. Also in mature cells from the 
immune system miR-125a seems to play a role. In fact, it has been reported 
overexpressed in classically activated macrophages 104,105. Its role in such context is still 
controversial. Indeed it has been shown to directly target TNFα and IL6 exerting anti-
inflammatory functions while others showed a pro-inflammatory role for this 
microRNA demonstrating its targeting against TNFΑIP3 that leads to increased 
expression and activation of NFkB 106. Similarly, a recent report 107 showed that 
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artificial overexpression of miR-125a in macrophages increased M1 features like iNOS 
expression, secretion of TNFα and IL12, phagocytosis of tumoral cells and T-cell 
activation. On the contrary, Banerjee and collaborators showed that miR-125a could 
directly target TNFα, IL12 and iNOS, consequently its blockade led to increased 
expression in such molecules 108. Consistently, in the same report it was shown that 
miR-125a artificial expression in macrophages led to increased expression of M2 
markers upon IL4 stimulation and increased phagocytosis of apoptotic cells but reduced 
bacterial killing. All these conflicting reports clearly link miR-125a to immune system 
but the real role of this miRNA in immune cells is still elusive. Previous unpublished 
data from our lab support the idea that in human macrophages miR-125a plays an anti-
inflammatory effect. In particular we have evidences that this microRNA is induced 
with a late kinetics in macrophages stimulated with LPS and its expression is further 
induced by IL10. Moreover, among the molecular targets of this miRNA we identified 
many molecules important for classical M1 functions like TLR4 itself, its co-receptor 
CD14, the adaptor molecule IRAK1 and the effector cytokines TNFα and IL6 together 
with the pro-inflammatory chemokines CCL3 and CXCL8. Indeed ectopic expression of 
miR-125a in the monocyte like cell line THP-1 resulted in decreased level of secreted 
pro-inflammatory molecules upon LPS stimulation, while miR-125a blockade led to the 
opposite result. Collectively these results prompted us to consider this miRNA as a 
molecular effector of IL10 signaling, exerting anti-inflammatory roles. 
 
2.1.3 miR-135b 
 
Human miR-135b gene maps in chromosome 1q32.1. It has been widely studied in 
oncologic context where it appears to exert opposing functions from one tumor type to 
the other. Some of these reports identified targets for this miRNA like, for example, 
STAT-6 109 and SMAD-4/5 110 that suggest a possible role for this miRNA in immune 
cells. Furthermore recent works directly linked induction of miR-135b to pollutants-
induced inflammation in the lung 111-113. Although miR-135b expression in inflamed 
lung was attributed to fibroblast and epithelial cells, possible contributions from innate 
immune cells were not ruled out. Hence, miR-135b appears to be an interesting and 
mostly unexplored miRNA in inflammation.  
 
2.2 Long Non Coding RNA 
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Long Non Coding RNAs (lncRNAs) are tautologically defined as RNA molecules 
longer than 200 nucleotides with low or no coding potential. The length threshold is 
arbitrarily defined to distinguish members of this class from the previous defined and 
better known classes of small non coding RNA like rRNA (ribosomal RNA), tRNA 
(transfer RNA), snRNA/snoRNA (small nuclear and small nucleolar RNA) and 
miRNA/siRNA (micro and small interfering RNA). The definition of lncRNA is further 
challenged by the observation that some molecules annotated as lncRNA may display 
unconventional or cryptic ORF as evidenced by experiments of Mass spectrometry in 
murine models 114. To further blur the boundary between RNA classes, maturation of 
some lncRNAs requires cleavage of primary transcript generating a mature lncRNA and 
a residual small noncoding RNA that may itself be functional 115. Moreover, some pri-
miRNA genes have been identified nested in host lncRNA sequences 116. Such an 
ephemeral definition of lncRNA category reverberates in a complex classification. To 
date, many different criteria have been proposed for lncRNA classification, included 
subcellular location, position in the genome relative to other annotated elements, 
sequence and structure conservation or association with biochemical pathways 117. 
Every criterion considered alone fails to fully categorise lncRNAs and different criteria 
show little overlap. Therefore a real classification is still elusive and will probably 
require contemporary use of several criteria. LncRNAs are transcribed by Pol-II and 
commonly share many features with mRNA, like 5’ capping and 3’ poly-A although 
lncRNA expression usually appears to be more specific with respect to tissue, condition 
and developmental stage 118. LncRNA transcripts may originate from intergenic regions, 
pure exonic, pure intronic or mixed intronic/exotic regions of a gene, either in sense or 
antisense orientation, as well as being associated with promoter sequences, repeated 
sequences or telomeric regions. This complex genomic landscape has been referred to 
as ‘Transcriptional Forest’, highlighting that multiple transcripts may share the same 
genomic space, just like trees in a thick forest, and furthermore, different mature RNA 
species may branch from a common primary transcript 74. As a class, lncRNAs are 
homogeneously distributed between nucleus and cytoplasm but many lncRNA species 
show a specific enrichment in subcellular locations 118. Since lncRNAs are commonly 
capped and poly-adenilated, they display stability similar to mRNA, although with some 
important exceptions. In fact, lncRNAs originating from splicing events lack of both 5’ 
cap and 3’ poly-A and are thus degraded at higher pace than mRNA. Similarly, 
lncRNAs that are also host genes for miRNAs undergo microprocessor-mediated 
cleavage resulting in a capped but not poly-adenilated transcript, that is more sensitive 
20 
 
to degradation through Nonsense Mediated Decay (NMD). Vice versa, circularRNAs 
(ciRNAS), although originating from splicing events through back-splicing or lariat 
stabilisation, have and half-life longer than the average lncRNA thanks to their circular 
shape that hides 5’ and 3’ terminals. To exert their biological functions, lncRNAs take 
advantage of both their sequence, that allows interaction by complementarity with other 
nucleic acids, and their 3D structure, that allows direct interaction with proteins. Thus in 
the nucleus these molecules are perfect targeting and scaffolding elements, able to 
orchestrate recruitment and assembling of the epigenetic machinery. Similarly, in the 
cytoplasm these molecules may take part in biochemical pathways by promoting the 
assembly of macromolecular complexes as a scaffolding element or on the contrary, 
may compete with elements of the complexes for the binding of their molecular 
partners. Since most of lncRNA functions depend more on structure than on pure 
sequence, they are less sensitive to mutations than coding genes and are therefore less 
conserved evolutionarily, although more than random sequences 119. Because of their 
wide array of molecular interaction with both genetic and protein elements and their 
proved role in directing epigenetic modifications, lncRNAs are suitable candidates as 
regulators of complex processes. Indeed, recent evidences progressively unveil lncRNA 
contribution in controlling cell proliferation, survival and differentiation in health and 
disease. In particular important roles for lncRNA molecules in the control of immune 
system development and function have been highlighted. A recent study profiled 
lncRNA expression in haematological precursors 120. More than 2500 transcripts 
mapped to lncRNAs were shared between precursors, while 159 were overrepresented 
in long term Hematopoietic Stem Cells (HSC). Depletion of one of these transcripts, 
named lnHSC1, resulted in abnormal myeloid differentiation. Another report showed 
that H19 is a lncRNA that acts recruiting the methyl-CpG binding protein (MBD1) and 
histone methyl transferases. It is important for methylation of imprinted loci but plays a 
role also in maintaining pluripotency in long term HSC. In fact, upon conversion from 
long term HSC to short term HSC this lncRNA is drastically decreased. Moreover, 
genetic ablation of this gene led to decreased number in long term HSC that was 
paralleled by an expansion of short term HSC. H19 favours long term staminality by 
inducing the silencing the pro-differentiating growth factor IGF2 121. At later stages, 
lncDC is enriched during monocyte to DC differentiation 122. Apparently it favours the 
conversion through a competing mechanism. In fact, lncDC interacts with C-terminus of 
cytoplasmic STAT3 and prevent it from binding SHP1, a cytosolic phosphatase. 
Increased levels of lncDC lead to increased phosphorilation and subsequent nuclear 
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translocation of STAT3. Beside differentiation, lncRNAs also play an important role in 
cell survival. Trophic signals for myeloid cells like IL3, IL5 and GM-CSF induce the 
expression of the Morrbid transcript that in turn acts in cis recruiting Polycomb complex 
to the promoter of the pro-apoptotic neighbouring gene Bcl2l11. As expected, lncRNAs 
also play a pivotal role during immune cell activation. A recent report catalogued more 
than 150 lncRNAs differentially expressed in monocytes/macrophages after LPS 
stimulation 123. Most of these transcript were in close proximity with known 
inflammation-related protein-coding genes. Interestingly, lncRNAs overexpressed in 
cells of the innate immunity under inflammatory conditions to some extent shared 
conserved microdomains that may be important for lncRNA connectivity and function. 
One of the first lncRNA molecules observed to be overexpressed following TLR 
pathway triggering is lincRNA-COX2 124. LincRNA-COX2 induction results in 
perturbation of almost 500 genes, among which stand out many important regulators of 
the immune response like the cytokines IL6, IL23, the TLR1 receptor and the 
chemokines CCL-5 and CX3CL1. LincRNA-COX2 effect on gene expression is 
mediated by its direct association with the Heterogeneous Nuclear Ribonucleoparticle 
type A and B (hnRNP A/B) that affect stabilisation, splicing and cytoplasmic transport 
of target mRNAs. Another ncRNA with similar effect is THRIL. Similarly to lincRNA-
COX2, THRIL is overexpressed downstream of TLR2 activation and affects expression 
of almost 300 genes included chemokines (CXCL10 and CCL-1) as well as cytokines 
(CSF-1, IL8 and TNFα). Also the mechanism is similar between the two, since THRIL 
is shown to associate with hnRNP L 125. A third molecule that shares this mechanism of 
action is lncRNA-13. It is already expressed at steady state and interacts with hnRNP-D 
and histone deacethylase (HDAC) maintaining transcriptionally silent many genes with 
pro-inflammatory effect. Upon TLR2 triggering, lncRNA-13 levels decrease, releasing 
its suppression on MyD88, STAT1/3 and TNFα 126. Intriguingly a SNP in the sequence 
of this transcript is associated with chronic inflammatory disease like celiac disease. 
Two other lncRNAs induced under inflammatory conditions are LETHE and PACER. 
These lncRNAs show similar mechanisms of action but opposed effects. In fact LETHE 
and PACER act through a competing endogenous mechanism sequestering respectively 
p65 and p50 subunits of NFkB. Differences in the outcome depend on the fact that 
while p65:p50 NFkB dimers have a pro-inflammatory effect, p50:p50 dimers exert anti-
inflammatory roles 127,128. Therefore binding of p50 by PACER stechiometrically 
favours p65:p50 dimer formation supporting inflammation 129. On the contrary, 
requisition of p65 performed by LETHE favours p50:p50 interaction with overall 
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dampening of the inflammatory response 130. NFkB is a nevralgic element in the control 
of innate immunity being the converging point of many inflammatory signaling 
pathways. As such it is a strategic target to broadly regulate inflammatory response. 
Therefore is no surprise that so many regulatory mechanism have developed to finely 
tune NFkB activity. Indeed in addition to the aforementioned lncRNAs affecting NFkB 
activation, a third molecule has lately been described with negative regulatory effect. It 
is called NKILA and apparently interacts with NFkB:IkB inactive complex and masks 
phosphorilation sites on IkB, thus preventing IkK mediated phosphorilation of IkB and 
its subsequent degradation that allows NFkB activation 131. NKILA expression is 
increased after exposure of macrophages to pro-inflammatory cytokines like TNFα and 
IL1b, thus it appears to act as a molecular brake to control inflammation.  
 
2.2.1 BLACAT1 
 
Bladder cancer associated transcript 1 (BLACAT1 also known as linc-UBC1) has 
initially been identified as the most highly expressed ncRNA in bladder cancer tissues 
as compared with adjacent normal tissue, hence the name bladder cancer transcript-1 132. 
It is annotated as a 3kb, mono-exonic gene in chromosome 1q32.1. BLACAT1 mainly 
localise in the nucleus where it directly interacts with SUZ12 and EZH2. These proteins 
assemble together and form the core of the Polycomb Repressive Complex 2 (PRC2). 
Consistently, treatment with siRNAs targeting BLACAT1 in bladder cancer cell lines 
resulted in decreased levels of H3K27 tri-methylation of known PRC2 modulated genes 
and was paralleled by increased transcript levels. While PRC2 target genes were 
modulated after BLACAT1 depletion, genes mapping in close proximity of BLACAT1 
itself were not affected. These results depose on behalf of an in trans effect of this 
lncRNA rather than an in cis effect. Other than in bladder cancer, BLACAT1 has been 
associated with many types of solid cancers like gastric cancer, colorectal tumours, lung 
adenocarcinomas and lung squamous carcinomas 133,134. In all these tumours, 
BLACAT1 overexpression correlated with poor prognosis due to increased metastasis 
and reduced survival rate. Consistently, BLACAT1 silencing in cancer cells led to 
reduced proliferation and motility in vitro that correlated with reduced metastasis in 
vivo. Overall these results depict BLACAT1 as a pro-oncogenic transcript that acts in 
trans through association with PRC2. Although a direct role for this lncRNA was 
proved in cancer cells, a possible role in immune cells has never been assessed so far, 
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although it is now widely recognised that immune system is crucial for cancer 
progression. 
 
2.3 A new layer of complexity: lncRNA-miRNA interactions 
 
Discovery of functional roles for ncRNAs completely revolutionised the field of 
molecular biology. These molecules have been proved to be capable of tightly regulate 
complex macromolecolar networks and cellular processes. The ability of these 
transcripts to simultaneously interfere with many targets greatly expanded the 
complexity of regulatory networks. In fact molecules from these classes can reciprocally 
affect members of the others. For example, miRNAs have been mapped inside lncRNA 
genes and their excision is a maturation step for both molecules 116. Furthermore, pri-
miRNAs may be considered all the way lncRNA and some of them may even have 
proper function other then being a precursor for microRNA and the balance between the 
two natures may depend on context. MicroRNA have also been reported to target 
lncRNA, negatively regulating their functions 90. On the contrary, a specific class of 
circular-lncRNA (ciRNA) are enriched in repeated miRNA responsive elements and act 
as a ‘sponges’, buffering the available cytoplasmic levels of mature miRNA 135. 
Moreover a recent report convincingly proved that a lncRNA was able to interfere with 
processing of a specific miRNA by competing with Drosha for its binding region on pri-
miRNA stem-loop structure 136. Overall these new classes of molecules appear to be two 
widely interconnected systems with regulatory roles on cellular behaviour, both at 
steady state and after stimulation, in health and pathology. Future studies will further 
characterise their interactions as well as their functions, possibly yielding a functional 
classification for lncRNAs.
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Aim of the study 
 
The first aim of this study is to further characterise the relevance of previously 
identified microRNAs on macrophage activation. In particular, animals selectively 
deficient for miR-125a in macrophages are studied in different inflammatory 
pathologies. With a similar approach, murine macrophages deficient for miR-9.1 are 
assayed in vitro to characterise cellular response to inflammatory stimuli in the absence 
of this regulator. 
The second aim of this work is to unveil a new layer of complexity in macrophage 
activation. We study the negative regulatory effect on miRNA processing exerted by a 
lncRNA that has never been characterised in immune cells before.
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Materials and Methods 
 
Genotyping 
 
Similar genotyping strategies were employed to identify WT and KO animals in both 
miR-9.1 and miR-125a mice. Routine genotyping was performed by PCR reaction on 
tail biopsies genomic DNA. Primers used for genotyping are reported in Table.1. PCR 
with ‘flox’ and ‘rev’ primers could confirm homozygosity for the floxed allele. 
Discrimination between KO and WT mice was allowed by genotyping for the CRE 
gene. Homozygosity for the band generated by ‘CRE null’ and ‘CRE rev’ primers 
indicated WT animals. On the contrary, heterozygosity for the ‘CRE null’/‘CRE rev’ 
and ‘CRE’/‘CRE rev’ generated bands identified KO animals. Effective deletion of 
targeted genes was assessed by end point PCR on macrophage gDNA using the 
common reverse ‘rev’ primer downstream to the loxp site and forward primers specific 
for either floxed allele ‘flox’ or deleted ‘del’ alleles. Results were analyzed by gel 
electrophoresis with intercalating dyes. Gel pictures were acquired with Gel Doc EZ 
System (BioRad) and analysed with Image Lab™ Software (BioRad). MiR-9.1 deletion 
efficiency was further proved by real-time qPCR using the same primers. 
Table.1 
Target Orientation Sequence 
125a flox FW ATTCAGTCCCAGCCCCAAAATCTA 
125a del FW CTCTCTCTGAGGCACTGTTTTGTC 
125a rev RW CTTCTCTAAGGGATGTGCCTGGTT 
9 flox FW CCGAAGTTCCTATTCCGAA 
9 del FW CCTTTCTGAGGTCTCGTCGT 
9 rev RW GCTTGCACTTTCCCAGTACTT 
CRE FW CCCAGAAATGCCAGATTACG 
CRE null FW TTACAGTCGGCCAGGCTGAC 
CRE rev RW CTTGGGCTGCCAGAATTTCTC 
 
Bone Marrow Derived Macrophages (BMdM) preparation 
 
Experimental mice were kept under SPF conditions. BMdM were obtained from 8-12 
weeks old male C57BL/6. Femurs were obtained, muscles were removed and washed in 
sterile IMDM (Lonza) and then both epiphyses were removed. The bone marrows were 
obtained by centrifugation (5000 rpm, 2 min) in a 1.5 mL sterile eppednorf tube. 
Erytrocytes were lysed by 5 min incubation in ACK buffer (150mM NH4Cl, 10mM 
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KHCO3, 1mM Triplex-EDTA). The obtained cells were either stained for FACS 
analysis or plated in 100mm x 20mm not treated polystyrene plates (corning). Percursor 
cells were then differenntiated in complete IMDM medium (10% FBS, 1% penicillin-
streptomycin, 1% glutamine) supplemented with murine mM-CFS (50ng/ml). After 7 
days of culture, macrophages (BMdM) were detatched using Accutase (Sigma-Aldrich) 
and plated at desired concentrations. After ON adhesion, macrophages were ready for 
subsequent experiments. 
 
Human Macrophage differentiation and polarization. 
 
Human monocytes were isolated from healthy donor buffy coats by two step gradient 
centrifugation using Ficoll-Paque (GE Healthcare) and Percoll (Amersham). Isolated 
monocytes were plated in RPMI without serum for 10 min. Non-adherent cells were 
discarded, and purified monocytes were cultured in 6 well at 2x106 cells/well in 2ml 
RPMI 1640 (Lonza) supplemented with 10% fetal bovine serum (FBS; Lonza), 1% 
penicillin–streptomycin (Lonza), and 1% glutamine (Lonza). Monocytes were 
differentiated in macrophages by exposure to 50 ng/ml recombinant human M-CSF for 
6 days. Resting macrophages were then polarized to M1 macrophages using 100 ng/ml 
LPS plus 20 ng/ml IFNγ or M2 macrophages using 20 ng/ml IL4 for 24 h before being 
evaluated. Resting macrophages (M0) were left untreated in culture medium. 
 
Cell Stimulation 
 
LPS from Escherichia coli serotype 055:B5 was purchased from Sigma- Aldrich. 
Human IL10, IFNγ, IL4, TGFβ and M-CSF were purchased from R&D Systems as well 
as murin INFg, TNFα and mM-CSF. Dexamethasone was from Sigma-Aldrich. Prior to 
stimulation, exhausted media were removed and cells were washed in PBS. Stimuli 
were prepared at the desired dilutions in complete cell colture media.  
 
RNA isolation and gene expression analysis 
 
Stimulated cells were harvested in TRIzol reagent (Ambion). Total RNA was purified 
using DirectZOL™ RNA Miniprep (ZymoResearch) according to the manufacturer's 
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instructions. Total RNA quantity and purity were determined at Nanodrop 2000c 
(ThermoFisher). First-strand cDNA was synthesized from 1 μg of total RNA in 50 μL 
of reaction mixture using High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems) according to manufacturer’s guidelines. Quantitative RT-PCR was 
performed using specific oligonucleotides (Table.2) and Fast SYBR® Green Master 
Mix 2X (Applied Biosystems). Reactions were assembled mixing cDNA (2ul of 5ng/ul 
dilutions from RT), Fast SYBR Green Master Mix (5 ul of 2x product), primers (0.5 ul 
for each 10uM primer dilutions) and water (3ul to final 10ul of reaction). For pri-miR-9 
isoform quantification, Taqman probes were preferred (Table.3, ThermoFisher) and 
performed in similar conditions using Fast TaqMan ® Master Mix 2x (Applied 
Biosystems). Reactions were performed on a VIIA-7 Real-Time PCR Detection System 
(Applied Biosystems). The thermal cycling conditions were standard fast-cycling 
conditions. Relative expression values were calculated using ΔΔCT method normalized 
on GAPDH as housekeeping. 
Table.2 
Terget Orientation Sequqnece 
pri-miR-155 
FW CAGATTTCCCCTTCCTGGTTT 
RW AGCTTTATAACCGCATGTGCATAC 
pri-miR-135b 
FW TCCACTCTGCTGTGGCCTAT 
RW AGCCCTACATGAGTTTGGGAC 
BLACAT 
FW GCATGGTTTCCCGAATCTATGC 
RW TTTGCCGGCATGCTTTTCAG 
KLF4 
FW TCTCCAATTCGCTGACCCAT 
RW CGGATCGGATAGGTGAAGCT 
cMyc-C 
FW ACAGGATACATCCTGTCCGT 
RW GCACAAGAGTTCCGTAGCTG 
GAPDH 
FW GATCATCAGCAATGCCTCCT 
RW TGTGGTCATGAGTCCTTCCA 
 
Table.3 
Assay Name Assay ID 
mmu-pri-miR-9.1 Mm04227702_pri 
mmu-pri-miR-9.2 Mm03306269_pri 
mmu-pri-miR-9.3 Mm03307250_pri 
 
Human macrophage miRNome profiling  
 
TaqMan low density array (TLDA) human miRNA assays (version 2.0; Applied 
Biosystems) were used to profile the macrophage miRNome in differently activate 
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phenotypes. Briefly, cDNA was obtained using the TaqMan reverse transcription kit 
and Megaplex primer pools A and B (version 2.0). PCR amplification was first 
performed using TaqMan PreAmp Master Mix (version 2.0). Lastly, TLDA cards A and 
B were loaded, and PCR was performed on a 7900HT fast real time PCR system 
(Applied Biosystems). Expression fold changes each miRNA were evaluated with ΔΔCt 
method using SDS (version 2.3) and SDS RQ Manager software (version 1.2). U6 was 
used as an endogenous control as it was found to be stably expressed across 
experimental condition (Fig.M1). 
 
 
 
MicroRNA isolation and Quantitative RT-PCR Analyses 
 
Stimulated cells were harvested in TRIzol reagent (Ambion). Total RNA was purified 
using DirectZOL™ RNA Miniprep (ZymoResearch) according to the manufacturer's 
instructions. For each sample, 100 ng of total RNA were reverse transcribed with 
individual stem-loop RT-primers using TaqMan miRNA assay (ThermoFisher). 
Subsequently, 10 ng of each individually synthesized cDNA were amplified in 10μL of 
final qPCR reaction with specific TaqMan probes (Table.4). Real-time PCR was 
performed on VIIA-7 Real-Time PCR Detection System (Applied Biosystems). Relative 
miRNAs expressions were determined by using the ΔΔCt method, normalizing the 
levels with U6 snRNA (human) or snoR202 (murine). U6 was chosen to improve 
consistency with preliminary TLDA analisys, while SnoR202 is widely used as 
endogenous control for miRNA and was found to be stable across all tested 
experimental conditions (Data not shown). 
 
Figure.M1 Stability of U6 across donors and conditions in TLDA assays. (A) Average Threeshold Cycle 
(CT) were calculated for three donors in all experimental conditions and were found to be acceptably 
stable ( = 0.60) 
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Table.4 
Assay Name Assay ID 
hsa-miR-125a-5p 002198 
hsa-miR-9 000583 
hsa-miR-155 002623 
hsa-miR-135b 002261 
U6 001973 
SnoR202 001232 
mmu-miR-155 002571 
 
Macrophage Transfection 
 
Differentiated were transfected with 100pmol of BLACAT1 LNA™ longRNA GapmeR 
(Exiqon), using TransIT-TKO Transfection Reagent (Mirus Bio), according to the 
manufacturer’s protocol. In brief, for transfection in 6-well plates, for each well 4ul of 
GAPmeR 50uM were mixed with 200ul of OPTIMEM medium (Gibco) and 8ul of 
TransIT TKO. GAPmeR containing liposomes were allowed to form for 30 min at RT. 
Mixes were finally added to the well drop by drop. After ON incubation, transiently 
transfected cell were further stimulated as indicated. 
 
ELISA assay 
 
Antibodies and detection reagents for ELISA assays were purchased from R&D 
Systems and used according to the manufacturer’s instructions. Samples were diluted so 
that the optical density fell within the optimal portion of a log standard curve. 
 
Sepsis 
 
Sepsis was assessed in mice employing well established models to test either SIRS or 
CARS resembling conditions. SIRS conditions were modelled by IP injection of 
increasing doses of LPS (30mg/kg, 50mg/kg, 100mg/kg). After stimulation, survival 
and body weight loss were monitored for a week. Endotoxin Tolerance was adopted as a 
model for CARS phases in sepsis. Either 8-12 week old mice or differentiated BMdM 
were pretreated with LPS (in vivo: 5mg/kg, in vitro: 10ng/ml) or PBS and allowed to 
recover ON. Tolerant and responsive subjects were then challenged again with higher 
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doses of endotoxin (in vivo: 50mg/kg, in vitro: 100ng/ml). Blood samples were 
withdrawn from stimulated mice after 1, 4 or 8 hours. Plasma were isolated and 
cytokine abundance tested by ELISA assay. For in vitro BMdM, ELISA assay were 
performed directly on supernatants 24 hours. 
 
Peritonitis 
 
Self-resolving peritoneal inflammation was induced as previously described 56. Briefly, 
1mg of Zymosan (Invivogen) was IP injected in 8-12 week old mice. At indicated time 
points (6, 24, 48, 72 hours) mice were sacrificed and peritoneal wash were performed to 
collect peritoneal exudate cells (PEC). Leukocytes were collected by centrifugation, 
stained and analyzed by FACS. 
 
Colitis 
 
Inflammation in the GI tract was induced exposing 8-12 week old mice to water-
dissolved, ad libitum-available dextran sulfate sodium (DSS, MP Biomedicals), 
according to well established protocols. After one week DSS was removed and pure 
H2O reintroduced allowing mice to recover over a week. Three cycles of DSS/H2O 
were performed, continuously monitoring disease activity index (DAI). DAI is the sum 
of scores attribute to body weight loss, stool consistency and presence of fecal blood. 
BW loss inferior to 1% scored 0, a score of 1 was assigned for BW losses comprised 
between 1% and 5% . A score of 2 was given to BW losses between 5-10%, 3 for 10-
15% BW loss and 4 for losses higher than 15%. Fecal consistency was arbitrarily 
assessed with respect to normal stools. Normal feci scored 0, impaired consistencies 
were valued 2, while diarrhea was scored 4. Similarly, absence of blood was considered 
0, presence of occult blood counted 2 while evident hemorrhage scored4. At end point, 
colons were isolated and measured in length. Macrophages were subsequently isolated 
from lamina propria and further analysed. 
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Macrophage Isolation from Colon lamina propria 
 
Isolated colons were longitudinally cut and extensively washed in PBS 1x and wash 
solution (HBSS 1x, 5% FCS) to eliminate fecal residues. Colons were then cut in pieces 
0.5 cm in length and incubated three times with warm EDTA solution at increasing 
concentrations (2.5 < 3.5 < 5 mM) for 20 min at 37°. After each round of incubation, 
colon pieces were filtered in a tea strainer. Subsequent EDTA treatment eliminated 
luminal mucosal epithelial layer, exposing lamina propria for enzymatic digestion. 
Excess EDTA was quenched by washing pieces with wash solution supplemented with 
2.5mM CaCl2. Residual colon pieces were further minced and incubated at 37° with 
wash solution with 1mg/ml Dispase, 1mg/ml DNAse, 0.25mg/ml Collagenase and 5mM 
CaCl2. Dissociated cells were filtered sequentially through 100um and 70um filters. 
Subsequently macrophage cells were purified by centrifugation on Percoll gradient. 
Isolated macrophages were counted and further purified using CD11b microbeads 
(Milteny) according to manufacturer’s instructions. 
 
Peritoneal Wash  
 
Peritoneal cells were collected by injecting 5ml of Physiological Saline in the 
peritoneum and by re-collecting the volume. 
 
Blood withdrawal 
 
Blood samples were collected from the retro-orbital sinus of 9-11 week-old WT and KO 
mice previously anesthetized with ketamine/xylazine Ketaset® CIII/Rompun®, dose 
100 mg/kg ketamine and 10 mg/kg xylazine. For FACS analysis blood samples were 
collected in Vacutainer blood collection tubes (EDTA, sodium citrate, heparin; BD) to 
prevent coagulation. Erythrocyte lysis was obtained incubating samples in ACK buffer 
for 5-10 minutes. Leukocytes were collected by centrifugation and further prepared for 
FACS analysis. For cytokine quantification in plasma, blood samples were collected in 
1.5ml Eppendorf tubes and kept in ice. Cellular components were subsequently pelleted 
by centrifugation (13000g for 10 min at 4°C) and plasma separated and stored at -80°C. 
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Phagocytosis 
 
For phagocytosis assay, 5x105 macrophages were seeded in 1 ml in 24 well plates and 
allowed to adhere ON. Contemporarily bacteria were grown in standard conditions. 
From ON cultures, 5x106 E.Coli particles per well were stained with 10uM Vybrant® 
CFDA SE Cell Tracker Kit (Invitrogen) in 1 ml for 30 min. Stained bacteria were 
washed three times with PBS. Bacterial pellet were resuspended in 500ul IMDM. Two 
hours prior to experiment, exhausted medium was removed from macrophages, cells 
were washed in PBS and only 0.5ml of IMDM were reintroduced. At T0, 0.5ml of 
stained bacteria were added to each well. After desired time interval supernatants were 
removed and kept in ice. Macrophages were detached with 400ul of Accutase and 
stained with anti-F4/80. Stained macrophages were analyzed by FACS analysis. 
Supernatants containing spared bacteria were serially diluted and plated. Bacteria were 
allowed to grow ON, then colonies were counted. 
 
FACS staining 
 
Prior to staining, cells were washed with FACS Buffer (PBS 1X, 1% Bovine Serum 
Albumin) and centrifuged at 1500 rpm for 5 min. Pellets were resuspended and stained 
with antibody mix at 4 °C for 30 min in the dark. Samples were then washed again with 
FACS Buffer and centrifuged at 1500rpm for 5 min. Finally, stained cells were fixed in 
350 μl FACS fix (PBS 1X, 1% paraformaldehyde) and incubated at RT for 30 min 
under chemical hood. After the fixation, samples were washed with FACS Buffer, 
centrifuged at 1500rpm for 5 min, resuspended in 700 μl of FACS Buffer. Fluorescent 
data were acquired with BD FACSCanto™ II and analyzed with FlowJo Software 
(v.9.3.2). The antibodies used are listed in Table.5.  
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Table.5 
Target Fluorophore Brand Clone 
CD45 V450 BD 30-F11 
CD11b PerCP-Cy5.5 BD M1/70 
Ly6G PE-Cy7 BD 1A8 
Ly6C FITC BD AL-21 
F4/80 AF647 Biolegend BM8 
TLR4 PE BD MTS510 
CD14 FITC BD rmC5-3 
CD86 PE eBioscience Sa2-8 
MHC-II (I-A/I-E) FITC eBioscience M5/114.15.2 
 
In silico prediction 
 
Pri-miR-135b hairpin sequence (MI0000810) was retrieved from miRbase 
(www.mirbase.org); BLACAT1 transcript sequence (ENST00000626538.1) was 
downloaded from ensembl (www.ensembl.org). Prediction of possible interactions 
between the two sequences were obtained executing the RNAduplex program from 
ViennaRNA package 137 in R environment (version V.3.4.2; R Core Team 2014). 
Graphical rendering of the predicted structures were designed using the RNAsmc and 
R4RNA libraries 138,139. In Script.1 we report a prototypical script developed for such 
analysis. 
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Script.1 R script for RNA-RNA interaction prediction and structure plotting 
 
# Inizialize workspace 
setwd("C:/Users/XXX/XXX") 
library(RNAsmc) 
library(R4RNA) 
 
# Upload and edit sequences 
fasta.seq<-read.fasta(“z.txt”) 
seq_1<-paste(fasta.seq[[1]][1:length(fasta.seq[[1]])], sep = ““, collapse= ““) 
seq_2<-paste(fasta.seq[[2]][1:length(fasta.seq[[2]])], sep = ““, collapse= ““) 
seq<- c(seq_1,seq_2) 
 
# Run RNAduplex command 
RNAduplex_path<-"C:/Users/XXX/ViennaRNA/RNAduplex" 
duplex<-system(RNAduplex_path, intern = TRUE, input = seq) 
 
# Edit RNAduplex output 
result<-unlist(strsplit(duplex, split=“ “)) 
seq_1.ext<-unlist(strsplit(result[4], split=“,”)) 
seq_2.ext<-unlist(strsplit(result[7], split=“,”)) 
mirna<-paste(fasta.seq[[1]][seq_1.ext[1]:seq_1.ext[2]], sep = “”, collapse= “”) 
lncrna<-paste(fasta.seq[[2]][seq_2.ext[1]:seq_2.ext[2]], sep = “”, collapse= “”) 
aligned_seq<- paste(mirna, “&”, lncrna, sep = “”, collapse = “”) 
output<-rbind(aligned_seq, result[1], result[8]) 
 
# Convert from dot-bracket notation to Helix notation 
wien<-unlist(strsplit(output[2], split= “”)) 
junction<-which(wien== “&”) 
wien[junction]<- “.” 
wien<-paste(wien, sep = ““, collapse = ““) 
wien<-viennaToHelix1 
lab<-unlist(strsplit(output[1], split= “”)) 
 
# Plot arc-diagrams and add annotations 
plotHelix(wien, bg=“gray95”) 
axis(1, at= 1:length(lab), labels= lab, pos= 0, cex.axis= 0.2, mgp= c(0,-0.5,0), tick = 
FALSE) 
lines(c(0,junction-1),c(0,0),lwd=2, col=“red”) 
lines(c(junction+1, length(wien)),c(0,0),lwd=2, col=“blue”) 
lines(c(16,38),c(0,0),lwd=2, col=“darkorange”) 
lines(c(0,16),c(0,0), lwd=2,col=“darkred”) 
text(c(length(wien[junction:0])/2,length(wien[junction:length(wien)])/2+length(wien[juncti
on:0])), c(-5,-5), labels = c(“pri-miR-135b”,”BLACAT1”),col = c(“red”,”blue”)) 
text(c(0,junction-1,junction+1,length(wien)), c(-2.5,-2.5,-2.5,-2.5), labels= 
c(ext_pri[1],ext_pri[2],ext_lnc[1],ext_lnc[2]), col=c(“red”,”red”,”blue”,”blue”), srt=45, 
cex=0.5, adj=1) 
text(250,100, labels= paste(“Energy:”, result[8], “kcal/mol”), cex = 0.75) 
text(27, -2.5, labels=“miR-135b”,cex=0.8, col=“darkorange”) 
text(8, -5, labels=“DROSHA\nBinding Site”,cex=0.8, col=“darkred”) 
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Results 
 
MicroRNA-125a and macrophage functions 
 
To generate a mouse strain lacking miR-125a selectively in macrophages, Ozgene Pty 
Ltd developed a breeding line carrying the miR-125a gene flanked by loxP regions on a 
C57Bl/6j background. Animals homozygous for the loxed allele were then crossed with 
a strain of mice (C57Bl/6j, purchased at Charles River International Inc) expressing the 
CRE-recombinase enzyme under control of the macrophage specific gene Lysozyme M 
gene (LyzM). Thus animals heterozygous for both genes were obtained and further 
crossed. MiR-125aflox/flox/Lyzm-CRE+/- and miR-125aflox/flox/Lyzm-CRE-/- were then 
selected from the progeny and bred together to generate littermates homozygous for the 
floxed allele but either CRE negative (miR-125alox/lox/Lyzm-CRE-/- , WT) or CRE 
positive (miR-125alox/lox/Lyzm-CRE-/+ , KO).In the KO mice, CRE heterozygosity was 
preferred to avoid loss of function of the LyzM gene. Pups born from the latter breeding 
were screened for both genes at weaning and were to be born at the expected ratio 
between sexes and genotypes (fig.1). To validate our KO model the effective deletion of 
the targeted genomic region was evaluated. Genomic DNA from total splenocytes and 
from bone marrow derived macrophages (BMdM)of WT and KO animals was 
recovered and evaluated by PCR amplification with primers specific for either the WT 
allele (#) or for the deleted one (*). Since deletion of the microRNA was expected to 
occur only in macrophages, PCR amplification with primers specific for the deleted 
allele will generatate a specific band in KO BMdM, but not in KO splenocytes nor in 
WT cells (both BMdM and splenocytes). Conversely, WT primers are expected to 
generate a band both in KO splenocytes and in WT cells. WT primers may reveal also 
incomplete deletion of the gene of interest in KO BMdM. PCR reactions showed 
efficient deletion of the floxed allele in KO animals (fig.1). To assess whether the 
deletion observed at genomic level was sufficient to efficiently silence miR-125a, the 
expression of miR-125a mature form in BMdM was evaluated by RT-PCR after LPS 
stimulation. As expected, LPS induced miR-125a expression in WT cells whereas its 
expression was strongly reduced in KO BMdM (fig.1). 
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Increasing evidences describe miR-125a as a key player in the regulation of 
hematopoietic stem cell self-renewal 1 and lineage differentiation140. To exclude 
possible alterations in cellular ratio between immune population at steady state 
following miR-125a knockdown, we evaluated the frequency of neutrophils, eosinophils 
and monocytes of KO and WT mice in peripheral blood and in bone marrow at steady 
state (fig.2). The frequency of neutrophils, expressed as percentage of CD45+ cells, did 
not differ between WT and miR-125a KO animals both in bone marrow (WT=33.5%, 
sd=5.7; KO=40.0%, sd=6.1) and in peripheral blood (WT=11.2% , sd=3.9; KO=17.4% , 
sd=6.7). The frequency of monocytes displayed the same trend in both compartments 
with higher abundance in bone marrow (WT=6.7%, sd=2.3; KO=8.1%, sd=1.7) as 
compared to the blood (WT=3.9%, sd=1.9; KO=2.7, sd=1.4). No differences between 
Figure.1 (A) Mice deficient for miR-125a selectively in macrophages were obtained from miR-
125aflox/flox/LyzM-CRE-/- and miR-125a wt/wt/LyzM+/+ founders. (B) Newborn were monitored for sex 
and genotype at wheening. (C) Selective genomic recombination was confirmed in macrophages at 
genomic level. (D) Kinetics of expression of mature form miR-125a expression levels in WT and KO BMdM 
in vitro stimulated with LPS (100ng/ml. Raw data are listed in Supplementary Table1). Two-way ANOVA 
displayed significant interaction between factors. Therefore, genotype-restricted one-way ANOVA were 
performed, followed by post-hoc Dunnet’s test for significant expression over time (WT: * p<0.05, ** 
p<0.01, *** p<0.001; KO: # p<0.05, ## p<0.01, ### p<0.001). Differences in the expression between WT 
and KO were determined by T-test between condition for each time point (° p<0.05, °° p<0.01, °°° 
p<0.001) 
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the groups were observed also in circulating eosinophils (WT=2.2%, sd=0.8; KO=2.6%, 
sd=1.1).  
Our data demonstrate normal frequencies for all the analyzed cell populations in both 
WT and miR-125a KO animals at steady state in agreement with O’Connel and 
coworkers 141. These results suggest that the critical role of mir125a in hematopoiesis 
and fate determination precedes acquisition of LyzM expression in precursor cells. 
Therefore, our next observations on this animal model are not biased by uneven basal 
level in cellular abundances. 
 
 
 
 
Considering the sensitivity of miR-125a to LPS stimulation in macrophages and its 
negative regulatory effect on TLR4 pathway itself, this microRNA appears to act as a 
molecular brake against excessive inflammation. The first context in which we 
attempted to test this hypothesis is sepsis. In case of sepsis, death occurs either in early 
phases or at later time points. Early death is due to the cytokine storm that takes place 
during SIRS 65. Genetic ablation of a negative regulator of TLR4 pathway, like miR-
125a, may lead to increased inflammation and exacerbation of death rate at early time 
Figure.2 Innate immune cell popuations were analyzed in (A) peripheral blood and (B) bone marrow 
compartments of WT and miR-125a KO. T-test was not significant for any of the cell type analyzed. 
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point of septic shock. To evaluate whether this was indeed the case, WT and KO 
animals were intraperitoneally injected (IP) with increasing doses of LPS and survival 
and body weight (BW) loss were monitored for a week (fig.3). Although we observed a 
correlation between administered dose and death rate (fig.3A), no differences in 
survival or BW could be detected between WT and KO animals at any of the tested 
concentrations (fig.3B). Although no difference in the survival rate was observed 
between the groups, blood sampling at early time points after stimulation with LPS at 
lethal dose 50 (LD50, 50mg/kg in our experimental setting) and subsequent ELISA 
quantification of TNFα, a mayor mediator of septic shock, displayed greatly reduced 
levels in KO animals (fig.3C). Taken together these results suggest that the lack of miR-
125a is impairing TLR4-dependent TNFα production, without any effects on survival 
rate. These results are in line with the observation that experimental anti-TNFα 
treatments in sepsis alone are not sufficient to increase survival 142,143. 
 
 
 
 
 
Figure.3 (A) WT mice exposed to increasing doses of LP show lethal dose 50 (LD50) at 50 mg/kg. (B) 
Surivival and BW loss in WT and KO mice esposed to LPS at LD50. (C) TNFα levels in plasma of mice 
exposed to LPS at LD50. Two-way ANOVA displayed significant interaction between factors. Therefore, 
genotype-restricted one-way ANOVA were performed, followed by post-hoc Dunnet’s test for significant 
expression over time (WT: *** p<0.001). Differences in the expression between WT and KO were 
determined by T-test between condition for each time point (## p<0.01) 
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Septic patients that survived early phases of SIRS can still develop CARS 144. The 
Immunosuppression observed in CARS may favour pathogen super-infection leading to 
patient death at later time points. miR-125a can be considered as a good candidate for 
mediating the immunosuppressing phase in sepsis. Therefore, we investigated the role 
of miR-125a in Endotoxin Tolerance, a suitable experimental model for CARS 145. ET 
is a condition characterised by macrophages hypo-responsiveness to noxious stimuli 
upon repetitive challenge. To evaluate a possible involvement of miR-125a in ET, WT 
and KO animals were primed with an IP injection of low dose of LPS (5mg/kg), 
followed by a LPS bolus at higher dose (50mg/kg). Blood samples were collected at 
different time points after second exposure and plasma levels of TNFα were assessed by 
ELISA (fig.4). As expected, repetitive stimulation with LPS decreased circulating TNFα 
in WT animals. On the contrary, but consistently with previous results, KO animals 
displayed reduced TNFα levels in plasma already after first stimulation but did not 
display any degree of tolerization. 
 
 
 
 
 
Alongside with systemic administration, we also tested repeated LPS stimuli in vitro on 
BMdM (fig.5). In these cells, repetitive stimulation with LPS led to reduced level of 
secreted TNFα but at the same extent both in WT and KO cells (fig.5A). In WT BMdM, 
ET induction correlates with increased levels of miR-125a , whereas KO cells displayed 
significantly lower miRNA expression in all conditions (fig.5B). FACS analysis showed 
that LPS tolerant macrophages and, to a lesser extent, LPS stimulated cells, increased 
the expression of analysed markers (fig.5C). The observed increase was generally more 
pronounced in the absence of miR-125, although this common trend reached statistical 
significance only for CD14 that notably is a direct target of this miRNA. 
Figure.4 Plasmatic levels of TNFα in response to single (squares) or repeated (circles) IP stimulations with 
LPS in WT (white symbols) or miR-125a KO (black symbols). Two way ANOVA displayed significant 
interaction between factors. One-way ANOVA evaluated single treatment effect over time relative to T0 
(*** p<0.001, **** p<0.0001). One-way ANOVA compared different conditions at every time point (# 
p<0.05) 
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An interesting set of observation links miR-125a expression to TLR pathway activation 
with a late kinetics 104,146, suggesting that miR-125a is involved in late inflammatory 
responses. Moreover, miR-125a is enhanced in the presence of IL10, a master regulator 
of resolving phases of inflammation. A third important observation is that miR-125a 
directly targets molecules important for signal transduction via the TLR pathways. Thus 
the emerging evidences suggest that this microRNA may be an important effector of 
IL10 anti-inflammatory properties, counteracting inflammation by reducing availability 
of important inflammatory signal transducers. To dissect in vivo the involvement of 
miR-125a in resolution of inflammation in vivo we adopted a model of self-resolving 
inflammation 56. We injected IP Zymosan, an inactive yeast lysate, and we monitored 
cellular dynamics in peritoneal cavity, blood circulation and bone marrow over time 
Figure.5 (A) TNFα production by LPS treated or tolerized (ET) BMdM from WT (white bars) or KO (black 
bars) animals. T-test was performed between conditions (* p<0.05). (B) miR-125a expression in WT or KO 
BMdM exposed to a single dose of LPS or tolerized. Two-way ANOVA displayed significant interaction 
between factors. Therefore, genotype-restricted one-way ANOVA were performed, followed by post-hoc 
Bonferroni’s test for significant expression over time (WT: ** p<0.01, *** p<0.001; ° p<0.05, °° p<0.01). 
Differences in the expression between WT and KO were determined by T-test between condition for each 
time point (# p<0.05). (C) Surface expression of inflammatory markers in treated (LPS), tolerized (ET) or 
untreated (NS) BMdM from WT (white bars) or KO (black bars) mice. T-test compared genotype effect 
across conditions (* p<0.05) 
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(Fig.6). 6 hours after stimulus peritoneal macrophages were reduced and were replaced 
by neutrophils and, to a lesser extent by eosinophils. Over time, the frequencies of 
granulocytes in the peritoneum were reduced whereas the frequencies of recruited 
monocytes and newly differentiated macrophages were increased (Fig.6A). In the blood, 
neutrophils and monocytes peaked at 6 hours after Zymosan injection and decreased 
over time, probably due to recruitment in the peritoneum. Instead, after an initial 
decrease, eosinophil levels in the blood remained constant (fig.6B). Neutrophil, 
eosinophil and monocyte frequencies in the bone marrow were reduced after 6 hours 
upon Zymosan treatment. It suggests an egress of these cells from the bone marrow 
toward the blood stream. Initial depletion of granulocytes and monocytes in the bone 
marrow was followed by a reactive increased production of these cells, as expected 
during inflammatory response (Fig.6C). Although cellular frequencies were in line with 
an ongoing local inflammatory status prone to resolution, no differences could be 
observed between WT and KO mice. 
 
 
 
 
  
Figure.6 Innate immune cell popuations were analyzed in (A) peritoneal cavity, (B) peripheral blood and 
(C) bone marrow compartments of WT (white squares) and miR-125a KO (black squares) at indicated time 
points after IP injection of 1mg of Zymosan. 
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MiR-125a appears to act as molecular mediator of IL10 anti-inflammatory effect. 
Therefore miR-125a depletion may resemble phenotypes observed in IL10 KO in 
experimental colitis 62,147. We applied a well-established protocol for in vivo 
development of chronic colonic inflammation 148. WT or KO mice were exposed to 
water-dissolved DSS, a chemical reagent that induces inflammation in colonic mucosa, 
for one week and then they were allowed to recover for two weeks. This stimulus-
recovery cycle was repeated three times and progression of disease was periodically 
monitored evaluating both body weight and disease activity index. The disease activity 
index is an arbitrary score that takes into account pathological signs like body weight 
loss, stool consistency and presence of faecal blood (Fig.7). Each DSS administration 
was associated to a sharp increase of the disease activity (Fig.7A) accompanied by BW 
loss (Fig.7B). At the end of last cycle, animals were sacrificed and the colon was 
isolated for further analysis. Post mortem evaluation of colon length showed no 
differences between the groups (Fig.7C). Although no differences were detected in any 
of the analysed parameters, macrophages isolated from lamina propria indeed displayed 
reduced miR-125a levels in KO mice (Fig.7D) confirming that miR-125a depletion in 
macrophages do not increase DSS sensitivity. 
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The role of miR-125a in macrophages is still under debate 107,108. Banerjee and 
colleagues showed that ectopic expression of miR-125a in macrophages leads to 
increased phagocytosis of thymocytes, that is considered as a feature typical of M2 
macrophages, counterbalanced by a reduced microbicidal activity, that is considered an 
M1 feature 108. Consistently, the artificial blockade of miR-125a leads to reduced 
phagocytosis (no data on the microbicidal activity in the same context were shown). 
Conversely, Zhao and colleagues showed that increased miR-125a levels correlate to 
increased phagocytosis of tumoral cells and with enhanced T-cell activation (both 
considered as M1 features) 107. To determine the role of mir125a in macrophages, we 
evaluated the phagocytosis of living E.Coli by WT or mir125a KO macrophages 
(Fig.8). WT and KO BMdM were challenged with CSFE-labelled E.Coli for different 
time points. The macrophage supernatant containing spared bacteria was removed, 
serially diluted and cultured over night (ON). On the other hand, treated macrophages 
were analysed by FACS for F4/80 expression (that reveal their differentiation state) and 
for acquired CFSE positivity, that is proportional to the number of bacteria engulfed. 
Almost all macrophages were expressing F4/80 at high levels (Fig.8A, panel3) and 
Figure.7 WT (white symbols) and miR-125a KO (black symbols) repetitively exposed to DSS monitored for 
DAI (A) and BW loss (B). End point evaluation of colon length (C) and miR-125a expression in lamina 
propria macophages (D). T-test compared genotype effect across conditions (** p<0.01) 
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almost 100% of them were also CFSE positive (Fig.8A, panel4). It indicates that the 
phagocytosis assay efficiently worked. Moreover, monitoring mean fluorescent intensity 
for CSFE in macrophages, the phagocytic index increased over time in both WT and 
KO macrophages but the lack of mir125a did not affect the phagocytic index of KO 
macrophages. Indeed, the phagocytic ability of KO macrophages is comparable to the 
one of WT macrophages (Fig.8B). Nevertheless, the supernatant of KO macrophages 
generated higher number of colonies compared to the supernatant of WT macrophages, 
indicating higher bacterial survival. It appears that although miR-125a is not playing a 
role in the ability of macrophages to phagocyte bacteria, macrophages lacking mir125a 
may be defective in extracellular killing mechanisms (Fig.8C). 
 
Figure.8 Phagocytic capacity of WT or KO miR-125a exposed to stained bacteria. (A) Gating strategy 
defining positive phagocytic events. Black dots indicate unstained samples, black histogram indicate 
macrophages exposed to unstained bacteria, red histogram indicate phagocytitc macrophages. (B) Extent 
of phagocytosis in WT (white symbols) and miR-125a KO (black symbols) over 2 hours. Two-way ANOVA 
displayed significant interaction between factors. Therefore, genotype-restricted one-way ANOVA were 
performed, followed by post-hoc Bonferroni’s test (WT: * p<0.05, *** p<0.001; ° p<0.05, °°° p<0.001). (C) 
Colony formation assay of bacteria spared from phagocytosis. T-test compared genotype effect across 
conditions (# p<0.05, ##p<0.01) 
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MicroRNA-9 and inter-species variability 
 
Another microRNA that may play a role in macrophages during inflammation is miR-9 
95. To determine miR-9 contribution to inflammatory process, we developed a strain of 
mice deficient in microRNA-9.1 gene exclusively in myelomonocytic lineage. The 
breeding strategy was similar to the one employed to generate KO mice for miR-125a in 
macrophages in order to have miR-9flox/flox/LyzM-CRE-/- (WT) and miR-9flox/flox/LyzM-
CRE-/+ (KO) animals. An equal ratios between WT and KO littermates was observed, 
ruling out that miR-9 deletion results in a lethal phenotype (Fig.9A). Effective deletion 
of mir-9 in KO BMdM (as compared to WT) was assessed (Fig.9B) by PCR 
amplification of genomic DNA using primer specific for either the floxed allele (*) or 
the deleted one (#). As expected, primers specific for the deleted allele produced a 
detectable band only in KO animals. To further confirm efficient recombination, we 
evaluated allelic abundance by real time PCR on genomic DNA with different sets of 
primers specific for each allele (Fig.9C). We observed that floxed allele was 
significantly decreased in BMdM from KO animals as compared to WT. Coherently KO 
macrophages also displayed increased levels in deleted allele, although not statistically 
significant. Sensitivity of this assay was hampered by high background signal during 
deleted allele quantification in WT animals. In fact, deletion-specific primers still find 
complementary regions in the floxed allele, although at a way too great distance to be 
properly amplified by real time PCR, resulting in nonspecific amplification. 
Collectively, these results show effective deletion of miR-9.1 gene in target cell 
population. 
 
 
 
 
 
Several inflammatory stimuli have been shown to induce miR-9 expression in 
macrophages. Consistently with previous reports, we found that miR-9 steadily 
Figure.9 (A) Newborn from mice deficient for miR-9 selectively in macrophages were monitored for sex 
and genotype at wheening. (B) Selective genomic recombination was confirmed in macrophages at 
genomic level. (C) Efficient recombination was confirmed in macrophages by quantitative PCR. T-test 
compared genotype effect across conditions (*** p<0.001) 
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increased over 24 hours following stimulation with LPS and, to a lesser extent, IFNγ 
(Fig.10A-B). Combined treatment with both LPS and IFNγ further increased miR-9 
expression (Fig.10C). Conversely, no effect could be observed for TNFα treatment 
(Fig.10D). Although our data are in line with previous evidences 95 and we observed an 
efficient deletion of mir9 in our conditional murine model, we didn't observe significant 
differences between WT and KO mice.  
 
 
Trying to justify this unexpected observation we treated BMdM with a combination of 
LPS and IFNγ for 24 hours (Fig.11). First, we confirmed the significant induction of 
mature form of miR-9 already 6 hours after stimulation (Fig.11A). Then, We focused on 
the three different isoforms of miR-9 precursors. We observed that the increase in 
mature form of miR-9 was not only driven by pri-miR-9.1 (as already reported in 
humans 95), but also by pri-miR-9.3 (Fig.11B). It suggests that miR-9 biology is not 
entirely conserved between mouse and human, excluding any further use of this animal 
model, at least in the immediate. 
 
Figure.10 MiR-9 expression monitored in WT (white symbols) or miR-9 KO (black symbols) BMdM after 
pro-inflammatory stimulation with (A) LPS, (B) IFNγ, (C) LPS+IFNγ and (D) TNFα. Two-way anova with 
post-hoc Sidak’s test (WT: ** p<0.01, *** p<0.001; KO °° p<0.01, °°° p<0.001) 
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Figure.11 Kinetics of mature form (A) and pri-miR-9 isoforms (B) in WT BMdM exposed to LPS+IFNγ. 
One-way ANOVA followed by post-hoc Dunnet’s test for significant expression over time (miR-9: * p<0.05; 
pri-miR-9.1: ° p<0.05; pri-miR-9.3: p<0.05 
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MicroRNA-135b and BLACAT1: waltz on a DEX tune 
 
MiR-135b is a microRNA largely studied in oncological contexts but little is known 
about his function in immune system. Surprisingly, this microRNA stood out as the 
most enriched miRNAs in M1 macrophages in our TLDA experiments (Fig.12A), 
suggesting that its expression may contribute to regulate the dramatic changes that these 
cell experience upon activation. In order to better define mir135b role in macrophage 
biology, we evaluated mir135b expression in different human polarized macrophages 
and we observed that LPS alone was sufficient to induce miR-135b levels to the same 
extent of the combined treatment, as already observed for other pro-inflammatory 
miRNA such as miR-155 (Fig.12B). On the contrary, M2-typical stimuli did not induce 
neither miR-135b nor miR-155 (Fig.12C-D). 
 
 
 
 
 
Figure.12 TLDA miRNA profiling from human M1 (A) or M2 (C) macrophages. Volcano plots showing fold 
change on M0 vs negative logaritm of p-values. Horizontal dashed line indicate threeshold p-value=0.05. 
Vertical dashed line represent cutoff of fold increase=2. Hsa-miR-155 (red dot) and hsa-miR-135b (green 
dot) are highly expressed following pro-inflammatory stimuli (B) but not following anti-inflammatory stimuli 
(D) 
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Interestingly, when we monitored the levels of the mature form and the precursor of 
miR135b following stimulation, we observed that LPS stimulation resulted in similar 
kinetics for both miR-155 and miR-135b. In fact, macrophages responded to LPS with 
induction of both pri-miRNAs already 3 hours post stimulation. Pri-miRNAs then 
decreased over time, converted into mature miRNAs that accumulated in the cytoplasm 
over 24 hours (Fig.13A). Unexpectedly, the stimulation of human macrophages with the 
synthetic glucocorticoid Dexamethasone (DEX) impacts differently on the expression 
levels of the two genes. Indeed, DEX mediated inhibition of miR-155 occurred already 
at pri-miRNA level, suggesting a conventional transcriptional silencing. Conversely, 
DEX treatment induced the up-regulation of pri-miR-135b expression, suggesting that 
the observed inhibition of the mature form occurs through an unconventional, post- 
transcriptional mechanism. (Fig.13B)  
 
 
 
To better understand the DEX effect on miR-135b maturation, we analysed the genomic 
region of the mapped miR-135b gene and we found that a recently annotated lncRNA 
(BLACAT1) was mapping in close proximity (<20 kb, Fig.14A). Since lncRNA have 
Figure.13 Mature form (white symbols) and pri-miRNA (black symbols) kinetics for miR-135b (left panels, 
circles) and miR-155 (right panels, squares) in human macrophages exposed to LPS (A) or 
dexamethasone (B). One-way ANOVA followed by post-hoc Dunnet’s test for significant expression over 
time (pri-miRNAs: * p<0.05, *** p<0.001, **** p<0.0001; mature-miRNAs: °° p<0.01, °°°° p<0.0001) 
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been reported to regulate expression and maturation of proximally produced transcript, 
we evaluated BLACAT1 expression after stimulation of human resting Macrophages 
with DEX or LPS. If LPS had minor or no effects on BLACAT1 expression, DEX 
induced BLACAT1 production over 72 hours, resembling the pri-miR-135b kinetics we 
observed before (Fig.14B-C). Interestingly, BLACAT1 expression levels at 24 hours 
correlates with pri-miR-135b abundance (r2=0.9597, Fig.14D), suggesting that these 
molecules are not only linked but they may actually be part of a single transcript. This 
observation is supported by the fact that both these genes map in the same intron and 
therefore may be expressed by the same host gene (LEMD1, Fig.12A). On the other 
side, the annotated distribution of chromatin accessibility markers (H3K27Ac, Fig.12A) 
and Polymerase II binding sites (POLR2A, Fig.12A) in this genomic region is 
compatible with the idea that these genes are regulated by independent promoters, 
although much experimental work is needed to ascertain which of the two models is 
real. 
 
 
 
 
 
A recent report demonstrated that a lncRNA can interfere with pri-miRNA processing 
136. It was shown that a direct interaction of 11 nucleotides between a lncRNA 
(Uc.283+A) and pri-miR-195 could take place in close proximity to the Drosha binding 
site, preventing pri-miRNA processing by that enzyme. This mechanism might justify 
our observation that DEX treatment on macrophages induces pri-miR-135b 
accumulation alongside BLACAT1 induction. In silico prediction of RNA-RNA 
interaction highlighted a high complementarity region between BLACAT1 and Drosha 
Figure.14 (A) Close genomic proximity between miR-135b and BLACAT1 genes. (B) BLACAT1 
expression kinetics in human macrophages following stimulation with LPS or dexamethasone. (C) Pri-miR-
135b expression kinetics in human macrophages following stimulation with LPS or dexamethasone. (D) 
Strict correlation between pri-miR-135b and BLACAT1 expression levels after 24h DEX treatmet (Slope= 
1.06; Rsquare=0.9597) 
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binding site on pri-miR-135b (Fig.15A). Surprisingly, homology between BLACAT1 
and pri-miR-135b was not restricted to the Drosha binding side, instead it appeared to 
spread across a wider region of the lncRNA, involving pri-miR-135b in almost its full 
length (Fig.15B) and forming a duplex characterised by a free energy (-85.0 kcal/mol) 
lower than the one predicted for pri-miR-135b hairpin structure (-65.0 kcal/mol). If this 
interaction effectively occurs, it may lead to destruction of the stem-loop structure 
necessary for Drosha binding. That being the case, overexpression of BLACAT1 may 
lead to pri-miR-135b accumulation by preventing Drosha binding through a previously 
undescribed mechanism. 
 
 
 
 
 
To demonstrate that BLACAT1 induction by DEX treatment correlates with pri-miRNA 
accumulation by inhibition of conversion to pre-miRNA, human macrophages were 
transfected with LNA-GAPmeRs targeting BLACAT1 and subsequently stimulated 
with DEX (Fig.16). As expected, BLACAT1-specific GAPmeRs were effective in 
Figure.15 In silico prediction of BLACAT1/pri-miR-135b interactions. Each point on the x-axis stands for a 
nucleotide; arcs indicate predicted interactions between nucleotides. (A) DROSHA binding site on pri-miR-
135b (dark red) shows high similiararity (12/16 nucleotide match) with a region comprised between 
nucleotide 842-860 of the BLACAT1 transcript (blue). (B) High homology is predicted between the whole 
pri-miR-135b hairpin structure (red) and nucleotides 1372-1536 of BLACAT1 (blue); DROSHA binding site 
and mature miRNA sequence are shown (dark red and orange, respectively.  
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diminishing BLACAT1 levels upon DEX stimulation (Fig.16A). The reduction of 
BLACAT1 levels was associated with a decrease of the pri-miR-135b abundance 
(Fig.16B) and it was consistent with the release of the mechanism converting pri-miR-
153b to pre-miR-135b. According with that, miR-135b was more expressed in treated 
macrophages upon BLACAT1 inhibition (Fig.16C). Importantly KLF4, that is one of 
the most important targets for miR-135b in macrophages, was reduced (Fig.16D-E), 
indirectly confirming the increase of miR-135b levels. Altogether these results identify 
BLACAT1 as a previously unrecognised lncRNA mediating anti-inflammatory effects 
of glucocorticoids. Moreover we propose interference with pri-miR-135b processing as 
a general mechanism of action for this lncRNA in macrophages. However, the 
molecular interactions that lead to the observed results need further detailed studies. 
 
 
 
Figure.16 BLACAT1-specific GAPmeRs efficiently inhibit DEX induced BLACAT1 expression (B). 
BLACAT1 inhibition results in reduced pri-miR-135b levels (B) but increased mature form miR-135b (C). 
Increased expression of miR-135b interferes with KLF4 (D) but not cMyc-C (E) transcript abundance. Two-
way ANOVA followed by post-hoc Bonferroni’s test evaluate GAPmeR effect in treated samples (* p<0.05, 
** p<0.01)  
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Discussion 
 
In the last years the complexity of the mononuclear phagocytic system has been 
progressively unveiled 9. Macrophage biology appeared to be far more complex than 
initially thought. Plasticity is now accepted as a fundamental feature of macrophages. 
Through plasticity, macrophages can adapt their behaviour to different phases of a 
pathologic state, allowing them to coordinate adequate responses 13,149,150. Macrophage 
plasticity relies on modifications in the epigenetic program. MicroRNAs and lncRNAs, 
thanks to their pleiotropic effect are involved in the regulation of complex cellular 
processes and therefore could participate in the regulation of macrophage plasticity. We 
and others identified miR-125a as an important miRNA that negatively regulate TLR4 
signaling pathway and therefore macrophage responses, favouring the resolution of 
inflammation 108. Here we described the generation of an animal model in which miR-
125a is selectively depleted in macrophages. Recent reports suggest that miR-125a may 
play important roles in haematopoiesis and myeloid differentiation sustaining the 
neutrophil fate 151. We found that miR-125a depletion did not alter frequencies of 
circulating mature immune cells, suggesting that LYZM expression, with concomitant 
miR deletion, occur after the critical period for miR-125a action on haematopoiesis. 
Genetic ablation of miR-125a in monocyte/macrophages had no effect on survival 
during SIRS even if mir125a resulted in decreased secretion of TNFα. Reduced TNFα 
levels in miR-125a KO mice as compared to WT were observed also during CARS 
response. A positive effect for miR-125a on TNFα release and the expression of pro-
inflammatory markers has already been reported 106,107. These results are in partial 
conflict with our previous observation and data available in the literature 108. 
Nevertheless, the debate is still open and up to date the only explanation for that is the 
use of different experimental settings. Moreover, we found that depletion of miR-125a 
in macrophages did not alter the clinical course neither of acute peritoneal inflammation 
nor of chronic colitis. Although they displayed reduced killing capacity, macrophages 
deficient for miR-125a maintained phagocytic abilities when challenged with bacteria. 
This result is consistent with increased iNOS expression in miR-125a transfected 
macrophages as reported by Zhao and collaborators, but exacerbates the conflict with 
previous data from Banerjee and collaborators 107,108. Overall we were not able to 
identify a clear phenotype in macrophages deficient for miR-125a. Rather than 
excluding possible roles for this miRNA in inflammatory processes, it suggests that a 
sort of compensatory mechanism takes place. This compensatory mechanism may 
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involve the production of miR-125a by other cell types other than macrophages. In fact, 
many cells, also not belonging to the immune system, are sensible to pro-inflammatory 
stimuli like LPS and IFNγ 152. Since in our model miR-125a deletion is restricted to 
macrophages, these other cells may still be capable of producing miR-125a. Moreover, 
it has been demonstrated that miR-125a could be transferred from a cell type to another 
through the secretion of microvescicles 153. If a similar mechanism would occur during 
inflammation, macrophages may receive miR-125a containing vescicles from 
surrounding cells. Although interesting, this model is unlikely to be responsible for our 
results. Indeed, we didn't see any differences between WT and KO in vitro 
differentiated macrophages, in the absence of any surrounding cell, and when miR-125a 
was quantified in macrophages its expression levels were always reduced in KO cells. 
Another possibility is that, since the efficiency of the deletion never reached 100%, 
residual expression of miR-125a in KO macrophages is sufficient to mediate its 
physiological functions. A miR-125a full KO model may help to demonstrate this 
hypothesis. Nevertheless, under inflammatory conditions miR-125a levels drastically 
increased, suggesting that high levels of miR-125a are necessary to exert its functions. 
Therefore, the miR-125a left over in KO macrophages can unlikely be sufficient to 
restore its functions. Finally, miR-125a functions may be compensated by other 
miRNAs. Indeed, it has been shown that a cluster of miRNAs can be induced upon pro-
inflammatory stimulation and it negatively regulates inflammation related pathways 
69,154. This hypothesis is intriguing but requires additional efforts to be properly 
addressed, due to several technical problems. 
Our studies on miR-9 were hampered by the unexpected discovery that, differently from 
human, murine macrophages increased the expression of miR-9 by inducing 
transcription of two different pri-miRNA gene isoforms. This result may be the 
consequence of poor conservation in the regulatory regions between these two species. 
This striking difference between two mammals enlightens how important the 
phylogenetic distance is and how experimental results valid for one of the two models 
needs to be carefully proven in the other.  
The last part of our work focused on the possible interaction between the lncRNA 
BLACAT1 and the pri-miR-135b. We found that in macrophages pro-inflammatory 
stimuli led to increased expression of pri-miR-135b with subsequent conversion into the 
mature form miR-135b. On the contrary, anti-inflammatory stimuli like dexamethasone 
induced the expression of pri-miR-135b even if it was not converted to its mature form. 
Furthermore, dexamethasone treatment induced the expression of the proximal lncRNA 
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BLACAT1. A clear linear correlation was observed between pri-miR-135b and 
BLACAT1 expression levels, raising the possibility that these two elements are 
transcribed as a single molecule. Analysis of the genomic region supports this 
possibility. In fact the lncRNA BLACAT1 and the pri-miR-135b map very close 
together and are nested in the intron of a gene coding for an orphan protein. Although 
very interesting, further experiments are needed to fully prove that lncRNA BLACAT1 
and the pri-miR-135b are transcribed as a single molecule. If this hypothesis will be 
proven, it will shed new light on the regulation of pro and anti-inflammatory responses 
in macrophages. Indeed, the pro-inflammatory signals may induce a weak activation of 
the promoter, resulting in shorter stretches of transcript that include the pri-miRNA 
alone, whereas the anti-inflammatory signals may result in a more stable transcription 
favoring the formation of a longer transcript which functions are still unknown. In silico 
predictions suggested a possible interaction between BLACAT1 and pri-miR-135b in a 
region that has been identified as crucial for drosha binding and thus for the processing 
of the pri-miRNA 136. At the same time, the in silico data predicted a second possible 
interaction that involves the pri-miR-135b with almost all its length. Both predictions 
may explain the accumulation of pri-miR-135b observed in the presence of BLACAT1. 
Nevertheless, both predictions are not sufficient to demonstrate whether the lncRNA 
BLACAT1 and the pri-miR-135b are two distinct molecules or are a single 
polyfunctional lncRNA. BLACAT1 cleavage mediated by GAPmeRs resulted in 
decreased amount of pri-miR-135b and a significant increase of the mature form miR-
13b. These results suggest that indeed BLACAT1 exerts a block on pri-miR135b 
maturation and that it can be released by targeting BLACAT1. If these elements are part 
of the same transcript and the block by BLACAT1 is operated through extensive 
pairing, the cleavage of one of the two elements may allow refolding of the second and 
thus its maturation. If BLACAT1 is a separated molecule and inhibits pri-miRNA 
processing by specific binding to a small region, its cleavage could lead to the release of 
this blocking mechanism. Considering our current knowledge, both models can be 
reliable. Therefore, further experiments are needed to demonstrate the separate or the 
common identity of the lncRNA BLACAT1 and the pri-miR-135b and the type and 
extent of their interactions. By addressing these questions, new light can be shed not 
only on the regulation of miRNA expression and lncRNA functions, but also on 
unknown features of macrophage biology regulated by epigenetic elements.
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Supplementary Material 
 
LPS 
(100ng/ml) 
Raw CT Summary T-Test 
Time (h) KO1 KO2 KO3 WT1 WT2 WT3 KO Avg KO SD WT Avg WT SD P Value 
0 29.05 28.98 29.71 26.51 27.66 27.77 29.25 0.33 27.32 0.57 0.022 
1 29.66 28.49 29.59 27.18 27.68 27.32 29.25 0.54 27.39 0.21 0.027 
4 29.22 28.13 30.86 26.78 27.85 26.43 29.40 1.12 27.02 0.60 0.075 
8 29.17 28.22 29.41 25.74 26.21 26.57 28.93 0.51 26.17 0.34 0.005 
24 27.16 26.41 28.35 24.41 23.96 24.85 27.31 0.80 24.41 0.36 0.022 
48 27.98 26.55 28.51 24.81 24.71 24.51 27.68 0.83 24.68 0.12 0.033 
 
 
Supplementary Table.1 Raw data for miR-125a response to LPS stimulation in KO and WT BMdM. Two-
tails unpaired T-test highlights significant increase in CT values in miR-125a KO cells (i.e reduced 
availability of transcript). 
